Sinovac Biotech (SVA) 20-F 25 Apr 16 2015 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2015shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	SINOVAC BIOTECH LTD
Entity Central Index Key	1,084,201
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	56,906,561
Trading Symbol	SVA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 63,834	$ 91,293
Restricted cash (note 4)	1,626	0
Accounts receivable - net (notes 5 and 11)	39,021	40,719
Inventories (note 6)	18,685	18,712
Prepaid expenses and deposits (including prepaid expenses to related party of 2015 - $352, 2014 - $157) (note 12 (b))	958	1,426
Deferred tax assets (note 14)	2,603	2,266
Current assets held for sale (note 3)	1,797	387
Total current assets	128,524	154,803
Property, plant and equipment (notes 8 and 11)	63,940	66,233
Prepaid land lease payments (notes 9 and 11)	9,574	10,261
Long-term inventories (note 7)	0	2,648
Long-term prepaid expenses (including prepaid expenses to related party of 2015 - $25, 2014 - $3) (note 12(b))	25	3
Prepayments for acquisition of equipment	328	1,387
Deferred tax assets (note 14)	593	515
Licenses (note 10)	0	352
Long-term assets held for sale (note 3)	0	2,328
Total assets	202,984	238,530
Current liabilities
Short-term bank loans and current portion of long-term bank loans and other debt (note 11)	21,775	47,375
Loan from a non-controlling shareholder (note 12 (a))	2,470	2,595
Accounts payable and accrued liabilities (note 13)	22,524	22,538
Income tax payable	1,643	1,101
Deferred revenue (note 15)	8,144	4,996
Deferred government grants (note 16)	1,202	530
Current liabilities held for sale (note 3)	243	699
Total current liabilities	58,001	79,834
Deferred government grants (note 16)	4,730	7,494
Long-term bank loans and other debt (note 11)	756	1,803
Deferred revenue (note 15)	0	7,191
Other non-current liabilities (note 14)	756	454
Long-term liabilities held for sale (note 3)	0	28
Total long-term liabilities	6,242	16,970
Total liabilities	$ 64,243	$ 96,804
Commitments and contingencies (notes 17 and 24)
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil	$ 0	$ 0
Common stock (note 18) Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 56,906,561 (2014 - 55,809,661)	57	56
Additional paid-in capital	109,944	108,243
Accumulated other comprehensive income	8,110	12,022
Statutory surplus reserves (note 20)	13,450	12,627
Accumulated deficit	(8,281)	(6,384)
Total shareholders' equity	123,280	126,564
Non-controlling interests (note 21)	15,461	15,162
Total equity	138,741	141,726
Total liabilities and equity	$ 202,984	$ 238,530

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense To Related Party Current	$ 352	$ 157
Prepaid Expense To Related Party Noncurrent	$ 25	$ 3
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	56,906,561	55,809,661
Common Stock, Shares, Outstanding	56,906,561	55,809,661

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales (note 23)	$ 67,414	$ 62,932	$ 71,774
Cost of sales	18,425	15,476	20,505
Gross profit	48,989	47,456	51,269
Selling, general and administrative expenses (including rent expenses incurred to related party of 2015 - $852, 2014 - $869, 2013 - $847) (note 12(b))	37,436	34,166	33,611
Provision (recovery) for doubtful accounts	(49)	329	(504)
Research and development expenses - (net of 2015- $16, 2014 - $nil, 2013 $nil in government research grants)	9,490	10,934	8,128
Loss on disposal and impairment of property, plant and equipment (note 8)	26	74	88
Government grants recognized in income	(1,637)	(104)	0
Total operating expenses	45,266	45,399	41,323
Operating income	3,723	2,057	9,946
Interest and financing expenses - (Including interest expenses incurred to related party, 2015 - $183, 2014 - $221, 2013 - $237) (note 12(b))	(1,920)	(3,407)	(3,031)
Interest income	1,155	2,684	2,167
Other income	73	1,312	329
Income from continuing operations before income taxes	3,031	2,646	9,411
Income tax benefit (expense) (note 14)	(2,516)	(1,458)	2,225
Income from continuing operations	515	1,188	11,636
Loss from discontinued operations, net of tax of nil (note 3)	(728)	(1,524)	(1,266)
Net income (loss)	(213)	(336)	10,370
Less: (income) attributable to non-controlling interests	(861)	(515)	(2,928)
Net income (loss) attributable to shareholders of Sinovac	(1,074)	(851)	7,442
Income (loss) from continuing operations	515	1,188	11,636
Loss from discontinued operations	(728)	(1,524)	(1,266)
Comprehensive income (loss)	(4,688)	(2,763)	13,056
Less: comprehensive (income)attributable to non-controlling interests	(298)	(207)	(3,244)
Comprehensive income (loss) attributable to shareholders of Sinovac	$ (4,986)	$ (2,970)	$ 9,812
Basic net income (loss) per share:
Continuing operations	$ (0.01)	$ 0.01	$ 0.15
Discontinued operations	(0.01)	(0.03)	(0.02)
Basic net income (loss) per share	(0.02)	(0.02)	0.13
Diluted net income (loss) per share:
Continuing operations	(0.01)	0.01	0.15
Discontinued operations	(0.01)	(0.03)	(0.02)
Diluted net income (loss) per share	$ (0.02)	$ (0.02)	$ 0.13
Weighted average number of shares of common stock outstanding
- Basic (in shares)	56,313,927	55,681,076	55,301,276
- Diluted (in shares)	56,313,927	56,114,202	55,802,338
Continuing Operations [Member]
Income tax benefit (expense) (note 14)	$ 2,516	$ 1,458	$ (2,225)
Foreign currency translation adjustments	(4,137)	(2,344)	2,589
Comprehensive income (loss)	(3,622)	(1,156)	14,225
Discontinued Operations [Member]
Income tax benefit (expense) (note 14)	0	0	0
Foreign currency translation adjustments	(338)	(83)	97
Loss from discontinued operations	0	0	0
Comprehensive income (loss)	$ (1,066)	$ (1,607)	$ (1,169)

Consolidated Statements of Com5

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Rent Expenses Incurred To Related Party	$ 852	$ 869	$ 847
Research And Development Expense Government Grants	16	0	0
Interest Expense, Related Party	183	221	237
Other Comprehensive Income (Loss), Tax	0	0	0
Discontinued Operations [Member]
Other Comprehensive Income (Loss), Tax	$ 0	$ 0	$ 0

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Statutory Surplus Reserves [Member]	Retained Earnings [Member]	Stockholders' Equity, Total [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2012	$ 129,435	$ 55	$ 106,246	$ 11,771	$ 11,808	$ (12,156)	$ 117,724	$ 11,711
Balance (in shares) at Dec. 31, 2012		55,091,561
Stock-based compensation (note 19)	281	$ 0	281	0	0	0	281	0
Exercise of stock options (note 18)	849	$ 1	848	0	0	0	849	0
Exercise of stock options (note 18) (in shares)		478,800
Subscriptions received (note 18)	18	$ 0	18	0	0	0	18	0
Other comprehensive income (loss)
- Other comprehensive income attributable to non-controlling interests	316	0	0	0	0	0	0	316
- Other comprehensive income attributable to shareholders	2,370	0	0	2,370	0	0	2,370	0
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests	2,928	0	0	0	0	0	0	2,928
- Net income (loss) attributable to shareholders of Sinovac	7,442	0	0	0	0	7,442	7,442	0
Balance at Dec. 31, 2013	143,639	$ 56	107,393	14,141	11,808	(4,714)	128,684	14,955
Balance (in shares) at Dec. 31, 2013		55,570,361
Stock-based compensation (note 19)	287	$ 0	287	0	0	0	287	0
Exercise of stock options (note 18)	512	$ 0	512	0	0	0	512	0
Exercise of stock options (note 18) (in shares)		239,300
Subscriptions received (note 18)	51	$ 0	51	0	0	0	51	0
Other comprehensive income (loss)
- Other comprehensive income attributable to non-controlling interests	(308)	0	0	0	0	0	0	(308)
- Other comprehensive income attributable to shareholders	(2,119)	0	0	(2,119)	0	0	(2,119)	0
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests	515	0	0	0	0	0	0	515
- Net income (loss) attributable to shareholders of Sinovac	(851)	0	0	0	0	(851)	(851)	0
- Transfer to statutory surplus reserves (note 20)	0	0	0	0	819	(819)	0	0
Balance at Dec. 31, 2014	$ 141,726	$ 56	108,243	12,022	12,627	(6,384)	126,564	15,162
Balance (in shares) at Dec. 31, 2014	55,809,661	55,809,661
Stock-based compensation (note 19)	$ 952	$ 0	952	0	0	0	952	0
Exercise of stock options (note 18)	$ 732	$ 0	732	0	0	0	732	0
Exercise of stock options (note 18) (in shares)	367,900	367,900
Subscriptions received (note 18)	$ 18	$ 0	18	0	0	0	18	0
2015 restricted shares issued (note 18)	0	$ 1	(1)	0	0	0	0	0
2015 Restricted shares issued (note 18) (in shares)		729,000
Other comprehensive income (loss)
- Other comprehensive income attributable to non-controlling interests	(563)	$ 0	0	0	0	0	0	(563)
- Other comprehensive income attributable to shareholders	(3,912)	0	0	(3,912)	0	0	(3,912)	0
Net income (loss) for the year
- Net income (loss) attributable to non-controlling interests	861	0	0	0	0	0	0	862
- Net income (loss) attributable to shareholders of Sinovac	(1,074)	0	0	0	0	(1,074)	(1,074)	0
- Transfer to statutory surplus reserves (note 20)	0	0	0	0	823	(823)	0	0
Balance at Dec. 31, 2015	$ 138,741	$ 57	$ 109,944	$ 8,110	$ 13,450	$ (8,281)	$ 123,280	$ 15,461
Balance (in shares) at Dec. 31, 2015	56,906,561	56,906,561

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows provided by (used in) operating activities
Income from continuing operations	$ 515	$ 1,188	$ 11,636
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
- Deferred income taxes	(518)	(162)	(2,225)
- Stock-based compensation	952	287	281
- Inventory provision	1,820	1,026	1,052
- Provision (recovery) for doubtful accounts	(49)	329	(504)
- Loss on disposal and impairment of property, plant and equipment	26	74	88
- Depreciation of property, plant and equipment and amortization of licenses	6,249	7,829	6,097
- Amortization of prepaid land lease payments	261	267	311
- Government grants recognized in income	(1,637)	(104)	0
- Accretion expenses	120	114	100
Changes in:
- Accounts receivable	41	(9,691)	(7,256)
- Inventories	10	(6,130)	(7,157)
- Income tax payable	576	899	7
- Prepaid expenses and deposits	434	(506)	243
- Deferred revenue	(3,639)	601	(675)
- Accounts payable and accrued liabilities	(434)	(3,999)	4,450
- Other non-current liabilities	333	454	0
-Restricted cash	(1,677)	0	0
Net cash provided by (used in) operating activities from continuing operations	3,383	(7,524)	6,448
Net cash used in operating activities from discontinued operations	(722)	(1,123)	(872)
Net cash provided by (used in) operating activities	2,661	(8,647)	5,576
Cash flows provided by (used in) financing activities
- Proceeds from bank loans	21,312	17,837	16,800
- Repayments of bank loans	(46,786)	(15,962)	(4,089)
- Proceeds from issuance of common stock, net of share issuance costs	732	512	814
- Proceeds from shares subscribed	18	51	18
- Government grants received	544	3,520	842
- Repayment of loan from a non-controlling shareholder	(16)	(649)	0
Net cash provided by (used in) financing activities from continuing operations	(24,196)	5,309	14,385
Net cash provided by financing activities from discontinued operations	0	0	34
Net cash provided by (used in) financing activities	(24,196)	5,309	14,419
Cash flows used in investing activities
- Proceeds from disposal of equipment	81	0	0
- Acquisition of property, plant and equipment	(5,299)	(10,913)	(5,133)
- Proceeds from disposal of subsidiary	801	0	0
Net cash used in investing activities from continuing operations	(4,417)	(10,913)	(5,133)
Net cash used in investing activities from discontinued operations	(98)	(90)	(43)
Net cash used in investing activities	(4,515)	(11,003)	(5,176)
Effect of exchange rate changes on cash and cash equivalents, including cash classified within current assets held for sale	(1,491)	(1,383)	1,182
Increase (decrease) in cash and cash equivalents, including cash classified within current assets held for sale	(27,541)	(15,724)	16,001
Less: Net increase (decrease) in cash classified within current assets assets for sale	(82)	(500)	703
Increase (decrease) in cash and cash equivalents	(27,459)	(15,224)	15,298
Cash and cash equivalents, beginning of year	91,293	106,517	91,219
Cash and cash equivalents, end of year	63,834	91,293	106,517
Supplemental disclosure of cash flow information:
Cash paid for interest	1,722	3,152	2,853
Cash paid for income taxes	2,058	491	0
Supplemental schedule of non-cash activities:
Acquisition of property, plant and equipment included in accounts payable and accrued liabilities	$ 2,220	$ 2,050	$ 2,015

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Basis of Presentation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”). They include the accounts of Sinovac Biotech Ltd., which is incorporated under the laws of Antigua and Barbuda, and its wholly owned or controlled subsidiaries (collectively, the “Company”). Place of incorporation Percentage of Date of (or ownership as Percentage of incorporation or establishment) of December ownership as of Name establishment /operation 31, 2015 December 31, 2014 Principal activities Sinovac Biotech (Hong Kong) Ltd. (“Sinovac Hong Kong”) October 2008 Hong Kong 100% 100% Investment holding company Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) (note 21) April 2001 People’s Republic of China (“PRC”) 73.09% 73.09% Research and development, production and sales of vaccine products Tangshan Yian Biological Engineering Co., Ltd. (“Tangshan Yian”) February 1993 PRC 100% 100% Research and development, production and sales of vaccine products Sinovac Biological Technology Co., Ltd. (“Sinovac R&D”) May 2009 PRC 100% 100% Research and development of vaccine products Sinovac (Dalian) Vaccine Technology Co., Ltd. (“Sinovac Dalian”) (note 21) January 2010 PRC 55% 55% Research and development, production and sales of vaccine products Sinovac Bitomed Co., Ltd. April 2015 PRC 100% - Distribution of vaccine products

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Significant Accounting Policies (a) Use of Estimates In preparation of the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates made by management include: provision for product returns, allowance for doubtful accounts, inventory provisions, useful lives of amortizable intangible assets, impairment of long-lived assets, fair value of options granted and related forfeiture rates, and realizability of deferred tax assets. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s consolidated financial statements could be materially impacted. (b) Cash and Cash Equivalents Cash equivalents consist of highly liquid investments that are readily convertible to cash generally with maturities of three months or less when purchased. (c) Restricted Cash Restricted cash is cash held as collateral for transactions the Company has entered into. As of December 31, 2015, the balance of $1,626 represents cash collateral held as a guarantee of an EPI (Expanded Programme on Immunization) sales contract which is restricted until December 2016. (d) Accounts Receivable The Company extends unsecured credit to its customers in the ordinary course of business and actively pursues past due accounts. The Company estimates an allowance for doubtful accounts based on historical experience, the age of the accounts receivable balances, credit quality of the Company’s customers, current economic conditions and other factors that may affect its customers’ ability to pay. (e) Inventories Prior to January 1, 2015, inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost or market with respect to finished goods and work in progress. The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-11 (“ASU 2015-11”), Simplifying the Measurement of Inventory, which the Company adopted on January 1, 2015. Subsequent to January 1, 2015, inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost or net realizable value with respect to finished goods and work in progress. The cost of work in progress and finished goods is determined on a weighted-average cost basis and includes direct material, direct labor and overhead costs. Net realizable value represents the anticipated selling price, net of distribution cost, less estimated costs to completion for work in progress. (f) Property, Plant and Equipment Property, plant and equipment are recorded at cost. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expenses as incurred. Equipment purchased for specific research and development projects with no alternative uses are expensed. Assets under construction are not depreciated until construction is completed and the assets are ready for their intended use. Gains and losses from the disposal of property, plant and equipment are recorded in loss on disposal and impairment of property, plant and equipment included in the consolidated statements of comprehensive income (loss). Depreciation of property, plant and equipment is computed using the straight-line method based on the estimated useful lives of the assets as follows: Plant and buildings 10 to 24 years Machinery and equipment 8 to 10 years Motor vehicles 4 to 5 years Office equipment and furniture 3 to 5 years Leasehold improvements Lesser of useful lives and term of lease (g) Prepaid Land Lease Payments Prepaid land lease payments represent amounts paid for the rights to use land in the PRC and is recorded at purchased cost less accumulated amortization. Amortization is provided on a straight-line basis over the term of the lease agreement, which is 28 to 49 years. (h) Licenses The Company capitalizes the patent payment and the purchased cost of vaccines if the vaccine has received a new drug certificate from the China Food and Drug Administration (“CFDA”) of China. If the vaccine has not received a new drug certificate, the purchase cost is expensed as in-process research and development. Licenses in relation to the production and sales of pharmaceutical products are amortized on a straight-line basis over their respective useful lives. The useful lives of inactivated hepatitis A and recombinant hepatitis A&B licenses are estimated to be ten years. Before August 15, 2012, the useful life for H5N1 licenses was estimated to be 20 years. Effective August 15, 2012, the remaining useful life was revised to three years expiring on December 29, 2015 as a result of amendment to the agreement with the licensor (note 24(c)). The weighted average useful lives of the acquired licenses are 9.16 years. Costs incurred to renew or extend the term of licenses are capitalized and amortized over the license’s useful life on a straight-line basis. (i) Impairment of Long-Lived Assets Long-lived assets including intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable from the future undiscounted net cash flows expected to be generated by the asset group. An asset group is identified as assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets. If the asset group is not fully recoverable, an impairment loss would be recognized for the difference between the carrying value of the asset group and its estimated fair value, based on the discounted net future cash flows or other appropriate methods, such as comparable market values. The Company uses estimates and judgments in its impairment tests and if different estimates or judgment had been utilized, the timing or the amount of any impairment charges could be materially different. The Company recorded impairment charges on long-lived assets for the year ended December 31, 2015 of $nil (2014 - $nil, 2013 - $57). (j) Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the carrying values and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such a position are measured based on the amount that is greater than 50% likely of being realized upon settlement. The Company recognizes a change in available facts after the reporting date but before issuance of the financial statements in the period when the change in facts occur, even if that new information provides a better estimate of the ultimate outcome of an uncertainty. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets. (k) Value-added Taxes Value-added taxes (“VAT”) collected from customers relating to product sales and remitted to governmental authorities are presented on a net basis. VAT collected from customers is excluded from revenue. Prior to July 1, 2014, the Company was subject to a VAT rate of 6%. Starting on July 1, 2014, the Company is subject to a VAT rate of 3%. (l) Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. The Company generally obtains purchase authorizations from its customers for a specified amount of products at a specified price and considers delivery to have occurred when the customer takes title of the products. The Company provides certain customers with a right of return. Revenue for inactivated hepatitis A, combined inactivated hepatitis A&B and seasonal influenza vaccines are recognized when delivery has occurred and the Company estimates return provision for these products. The product return provisions for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine are estimated based on historical return and exchange levels as well as the inventory levels and the remaining shelf lives of the products in the distribution channels. As of December 31, 2015, the sales return provision for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine was $5,900 (December 31, 2014 - $3,553). Private pay sales return provision of inactivated hepatitis A and combined inactivated hepatitis A&B as a percentage of sales was 13.6% and 8.6% in 2015 and 2014, respectively. The Company does not accept returns for hepatitis products sold under the Expanded Program on Immunization and exports. As such, no sales returns are estimated for these sales. The product return provision for seasonal influenza vaccines is estimated based on actual sales returns and expected sales returns up to the end of the flu season because the Company generally accepts returns before the end of the flu season. As of December 31, 2015, the sales return provision for seasonal influenza vaccine returns was approximately $1,462 (December 31, 2014 - $1,320). Revenue for animal and mumps vaccines without a right of return provided to customers is recognized when delivery has occurred. Revenue for animal and mumps vaccines with a right of return provided to customers is recognized when payments are collected from customers as the Company currently does not have sufficient historical data to estimate returns for these products. Deferred revenue is generally related to government stockpiling programs and advances received from customers. For government stockpiling programs of H5N1 vaccines, the Company generally obtains purchase authorizations from the government for a specified amount of products at a specified price and no rights of return are provided. Revenue is recognized when the government takes delivery of the products. If the products expire prior to delivery, these expired products are recognized as revenue once cash is received and the products have expired and passed government inspection. (m) Shipping and Handling Shipping and handling fees billed to customers are included in sales. Costs related to shipping and handling are recognized in selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). For the year ended December 31, 2015, $1,389 of shipping and handling costs was included in selling, general and administrative expenses (2014 - $1,235, 2013 - $1,215). (n) Advertising Expenses Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $851 for the year ended December 31, 2015 (2014 - $268, 2013 - $474). (o) Research and Development Research and development ("R&D") costs are expensed as incurred and are disclosed as a separate line item in the Company’s consolidated statements of comprehensive income (loss). R&D costs consist primarily of the remuneration of R&D staff, depreciation, material, clinical trial costs as well as amortization of acquired technology and know-how used in R&D with alternative future uses. R&D costs also include costs associated with collaborative R&D and in-licensing arrangements, including upfront fees paid to collaboration partners in connection with technologies which have not reached technological feasibility and did not have an alternative future use. Reimbursement of R&D costs for arrangements with collaboration partners is recognized when the obligations are incurred. Under certain R&D arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific development, regulatory and/or commercial milestones. Before a product receives regulatory approval, license fees and milestone payments made to third parties are expensed as incurred. License fees and milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the remaining life of the agreement with third parties. (p) Government Grants Government grants received from the PRC government by the PRC operating subsidiaries of the Company are recognized when there is reasonable assurance that the amount is receivable and all the conditions specified in the grant have been met. Government grants for R&D are recognized as a reduction to R&D expenses when the expenses are incurred in the same period when the conditions attached to the grants are met, or recognized as government grants recognized in income in the period when the conditions are met after the expenses are incurred. Government grants for property, plant and equipment are deferred and recognized as a reduction to the related depreciation and amortization expenses in the same manner as the property, plant and equipment are depreciated. Interest subsidies are recorded as a reduction to interest and financing expenses in the consolidated statements of comprehensive income (loss), or recorded as a reduction to interest capitalized if the subsidies granted are related to a specific borrowing associated with building a qualifying asset. For government loans received at below market interest rate, the difference between the face value of the loan and fair value using the effective interest rate method is recorded as deferred government grants. Accretion expense is recorded in interest and financing expense and the government grant will be recognized as “government grants recognized in income” in the consolidated statement of comprehensive income (loss) when the government loan is fully repaid. (q) Retirement and Other Post-retirement Benefits Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company makes contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no legal obligation for the benefits beyond the contributions. The total amounts for such employee benefits, which were expensed as incurred was $3,577 for the year ended December 31, 2015 (2014 - $3,338, 2013 - $3,083). (r) Foreign Currency Translation and Transactions The Company maintains their accounting records in their functional currencies, U.S. dollars (“US$”) for the Company and Sinovac Hong Kong and Renminbi Yuan (“RMB”) for the PRC subsidiaries. The Company uses the US$ as its reporting currency. At the transaction date, each asset, liability, revenue and expense is re-measured into the functional currency by the use of the exchange rate in effect at that date. At each period end, foreign currency monetary assets, and liabilities are re-measured into the functional currency by using the exchange rate in effect at the balance sheet date. The resulting foreign exchange gains and losses are included in selling, general and administrative expenses. The Company recognized foreign exchange gains (losses) of $(886) for the year ended December 31, 2015 (2014 - $(619), 2013 - $650). The assets and liabilities of the PRC subsidiaries, Sinovac Beijing, Tangshan Yian, Sinovac R&D, Sinovac Dalian and Sinovac Bitomed are translated into US$ at the exchange rates in effect at the balance sheet date. Revenue and expenses are translated at average exchange rates. Gains and losses from such translations are recorded in accumulated other comprehensive income, a component of shareholders’ equity. Gains and losses on intra-entity foreign currency transactions that are of a long-term-investment nature was $560 for year ended December 31, 2015 (2014 - $294, 2013 - $235) which was recorded in accumulated other comprehensive income, a component of shareholders’ equity. (s) Stock-based Compensation Compensation expense for costs related to all share-based payments, including grants of stock options, is recognized through a fair-value based method. The Company uses the Black-Scholes option-pricing model to determine the grant date fair value for stock options. The Company uses the grant date stock price to determine the grant date fair value of restricted shares. The Company has elected to recognize share-based compensation costs using the straight-line method over the requisite service period with a graded vesting schedule, provided that the amount of compensation costs recognized at any date is at least equal to the portion of the grant date value of the awards that are vested at that date. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share based compensation costs are recorded net of estimated forfeitures such that expense is recorded only for those awards that are expected to vest. (t) Comprehensive Income (loss) The Company’s comprehensive income (loss) consists of net income (loss) and foreign currency translation adjustments. (u) Earnings (loss) Per Share Earnings (loss) per share is calculated in accordance with Accounting Standards Codification (“ASC”) 260 Earnings per Share (v) Operating Leases Leases are classified as capital and operating depending on the terms and conditions of the lease agreement. Leases that transfer substantially all the benefits and risks incidental to ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases where rental payments are expensed as incurred. There are no capital leases for the periods presented. (w) Fair Value Measurements Assets and liabilities subject to fair value measurements are required to be disclosed within a specified fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: · Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. · Level 3 — Unobservable inputs for the asset or liability. As of December 31, 2015 and 2014, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis. The carrying values of cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities and short-term bank loans and the current portion of long-term debt approximate their fair value because of their short-term nature. The fair values of long-term bank loans and other debt are estimated based on the discounted value of future contractual cash flows which approximates their carrying value due to the fact they are predominately stated at variable rates based on the People’s Bank of China. Fair value of the long-term bank loans and other debt are determined based on level 2 inputs. The Company measures property, plant and equipment at fair value on a non-recurring basis only if an impairment charge were to be recognized. There were no non-recurring fair value measurements for the years ended December 31, 2015 and 2014. (x) Concentration of Risks Exchange Rate Risks The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between the US$ and the RMB. In 2015, foreign exchange gains (losses) of $(886) is included in selling, general and administrative expenses (2014- $(619), 2013 - $650). As at December 31, 2015, cash and cash equivalents of $46,923 (RMB 304 million) is denominated in RMB and are held in PRC and Hong Kong (December 31, 2014 - $71,968 (RMB 447 million)). Currency Convertibility Risks Substantially all of the Company’s operating activities are transacted in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with other information such as suppliers’ invoices, shipping documents and signed contracts. Concentration of Credit Risks Financial instruments that potentially subject the Company to concentration of credit risks consist primarily of cash and cash equivalents, restricted cash and accounts receivable, the balances of which are stated on the consolidated balance sheets which represent the Company’s maximum exposure. The Company places its cash and cash equivalents and restricted cash in good credit quality financial institutions in Hong Kong and China. Concentration of credit risks with respect to accounts receivables is linked to the concentration of revenue. The Company’s customers are mainly various government agencies in China. For the year ended December 31, 2015, one of the Company’s customers accounted for 14% of the Company’s total revenue. No single customer accounted for more than 10% of total sales for the years ended December 31, 2014 and 2013 except for government stockpile purchases revenue recognized in 2013. To manage credit risk, the Company performs ongoing credit evaluations of customers’ financial condition. Interest Rate Risks The Company is subject to interest rate risk. Other than a loan with carrying value of $1,861 and loan from a non-controlling shareholder of $2,470 with fixed interest rates as at December 31, 2015, other interest-bearing loans are charged interest at variable rates based on the People’s Bank of China (note 11). (y) Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (Topic 606), where a single, global revenue recognition model applies to most contracts with customers. Revenue will be recognized in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled, subject to certain limitations. In August 2015, the FASB issued ASU 2015-14, where the effective date of ASU 2014-09 was extended to annual periods beginning after December 15, 2018. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard. In August 2014, the FASB issued ASU No. 2014-15 (“ASU 2014-15”), Going Concern. Management of the Company will be required to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. The Company will adopt ASU 2014-15 on January 1, 2017, and does not expect the adoption of this standard will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). The guidance would require that debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of debt liability, consistent with debt discounts or premiums, rather than an asset. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early adoption is permitted. The Company is currently evaluating the impact, if any, of the adoption of ASU 2015-03 on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17 (“ASU 2015-17”), Income Taxes. To simplify the presentation of deferred income taxes, ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position, applicable to all entities that present a classified statement of financial position. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. While the Company is still assessing the impact on its consolidated financial statements of adopting this standard, it does not believe that the adoption of this guidance will have a material impact on its consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments. ASU 2016-01 requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements. That presentation provides financial statement users with more decision-useful information about an entity’s involvement in financial instruments. The guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard. In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases. ASU 2016-02 requires recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. The guidance is effective for annual periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard. In March 2016, the FASB issued ASU No. 2016-09 (“ASU 2016-09”), Compensation – Stock Compensation. Under ASU 2016-09, the Company can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Discontinued Operations In December 2015, the Company committed to a plan to sell 100 2,069 13 776 5.03 Results of the discontinued operations are summarized as follows: For the year ended December 31, 2015 2014 2013 Sales $ 112 $ 169 $ 750 Cost of sales 406 1,017 768 Gross loss (294) (848) (18) Selling, general and administrative expenses 459 621 927 Research and development expenses 22 100 256 Total operating expenses 481 721 1,183 Operating (loss) (775) (1,569) (1,201) Other income (expense) 47 45 (65) (Loss) before income taxes (728) (1,524) (1,266) Income tax benefit (expense) - - - (Loss) from discontinued operations, net of income tax $ (728) $ (1,524) $ (1,266) The following table summarizes the carrying amounts of the major classes of assets and liabilities held for sale in the consolidated balance sheets as of December 31, 2015 and 2014, respectively: December 31, December 31, 2015 2014 Cash and cash equivalents $ 143 $ 225 Prepaid land lease payments 128 144 Property, plant and equipment 1,450 2,184 Other assets held for sale 76 162 Total assets held for sale 1,797 2,715 Accounts payable and accrued liabilities 217 699 Other liabilities held for sale 26 28 Total liabilities held for sale $ 243 $ 727 In February 2016, the Company completed the disposal of Tangshan Yian (note 25).

Restricted Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents Disclosure [Text Block]	4. Restricted Cash As of December 31, 2015, the balance of $ 1,626 December 31, December 31, 2015 2014 Restricted Cash $ 1,626 $ -

Accounts Receivable - net

Accounts Receivable - net	12 Months Ended
	Dec. 31, 2015
Loans and Leases Receivable Disclosure [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Accounts Receivable – net December 31, December 31, 2015 2014 Trade receivables (note 11) $ 40,733 $ 42,423 Allowance for doubtful accounts (2,415) (2,571) 38,318 39,852 Other receivables 703 867 Total accounts receivable $ 39,021 $ 40,719 Accounts receivables with a carrying value of $ 5,403 35 Accounts receivables with a carrying value of $ 5,641 35 The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company estimates the allowance based on known troubled accounts, historical experience, the age of the accounts receivable balances, credit quality of the Company’s customers, current economic conditions, and other factors that may affect customers’ ability to pay. The Company records its allowance for doubtful accounts based upon its assessment of various factors. As of December 31, 2015, the Company provided 100 100 71.3 100 38.6 56.3 13.6 18.5 1.4 1.8 For the year ended December 31, 2015, the Company changed its estimates of the allowance for doubtful accounts due to an improved historical trend of collecting accounts aged three years or more. The change in estimate resulted in an increase to income from continuing operations and net income attributable to shareholders of Sinovac of $ 375 274 0.00 0.00 The Company’s maximum exposure to credit risk at the balance sheets date relating to trade receivables is summarized as follows: December 31, December 31, 2015 2014 Aging within one year, net of allowance for doubtful accounts $ 34,495 $ 35,130 Aging greater than one year, net of allowance for doubtful accounts 3,823 4,722 Total trade receivables $ 38,318 $ 39,852

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure Excluding Noncurrent Inventory [Text Block]	6. Inventories December 31, December 31, 2015 2014 Raw materials $ 2,450 $ 2,603 Work in progress 3,636 4,056 Finished goods 12,599 12,053 Inventories $ 18,685 $ 18,712 For the year ended December 31, 2015, the Company charged $ 2,154 1,764 1,790 For the year ended December 31, 2015, the cost of sales includes $ 1,820 1,026 1,052

Long-term Inventories

Long-term Inventories	12 Months Ended
	Dec. 31, 2015
Long Term Inventories Disclosure [Abstract]
Long Term Inventories Disclosure [Text Block]	7. Long-term Inventories December 31, December 31, 2015 2014 Work in progress $ - $ - Finished goods - 2,648 Long-term Inventories $ - $ 2,648 Long-term inventories represent H5N1 vaccines with remaining shelf lives over one year and not expected to be sold within one year. These vaccines are for government stockpiling purposes.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8. Property, Plant and Equipment December 31, December 31, 2015 2014 Cost Construction in progress $ 13,256 $ 8,206 Plant and buildings 30,852 32,211 Machinery and equipment 39,700 40,596 Motor vehicles 1,570 1,747 Equipment and furniture 2,566 2,542 Leasehold improvements 12,911 13,232 Total cost $ 100,855 $ 98,534 Less: Accumulated depreciation Construction in progress $ - $ - Plant and buildings 8,059 6,957 Machinery and equipment 20,458 17,876 Motor vehicles 1,408 1,567 Equipment and furniture 1,830 1,707 Leasehold improvements 5,160 4,194 Total accumulated depreciation $ 36,915 $ 32,301 Property, plant and equipment, net $ 63,940 $ 66,233 The buildings of the Changping facilities of Sinovac Beijing with a net book value of $ 13,505 87.5 The buildings of Sinovac Beijing with a net book value of $ 2,568 16.6 ). The buildings of Sinovac Dalian with a net book value of $ 5,344 34.6 Depreciation expense for the year ended December 31, 2015 was $ 5,897 7,458 5,662 Loss on disposal of equipment for the year ended December 31, 2015 was $ 26 74 31

Prepaid Land Lease Payments

Prepaid Land Lease Payments	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Prepaid Land Lease Payments [Text Block]	9. Prepaid Land Lease Payments December 31, December 31, 2015 2014 Prepaid land lease payments $ 11,147 $ 11,638 Less: accumulated amortization 1,573 1,377 Net carrying value $ 9,574 $ 10,261 The prepaid land lease payments of the Changping facilities of Sinovac Beijing with a net book value of $ 2,724 17.6 The prepaid land lease payments of Sinovac Beijing with a net book value of $ 327 2.1 The prepaid land lease payments of Sinovac Dalian with a net book value of $ 3,548 23.0 Amortization expense for prepaid land lease payments for the year ended December 31, 2015 was $ 261 267 311

Licenses

Licenses	12 Months Ended
	Dec. 31, 2015
Licenses [Abstract]
Intangible Assets Disclosure [Text Block]	10. Licenses December 31, 2015 Accumulated Net book Cost amortization value Inactivated hepatitis A $ 3,261 $ 3,261 $ - Combined inactivated hepatitis A&B 470 470 - H5N1 licenses (note 24(c)) 1,419 1,419 - Total $ 5,150 $ 5,150 $ - December 31, 2014 Accumulated Net book Cost amortization value Inactivated hepatitis A $ 3,405 $ 3,405 $ - Combined inactivated hepatitis A&B 490 490 - H5N1 licenses (note 24(c)) 1,482 1,130 352 Total $ 5,377 $ 5,025 $ 352 On August 15, 2011, the Company entered into a non-exclusive main license agreement together with three sublicense agreements with Medimmune, LLC (“Medimmune”) to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. The Company amortized the patent fee on a straight-line method basis over the estimated useful life of 20 Amortization expense for the licenses was $ 352 371 435

Bank Loans and Other Debt

Bank Loans and Other Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	11. Bank Loans and Other Debt December 31, 2015 2014 China Merchants Bank (a) $ 4,631 $ 4,835 Bank of Beijing (b) 2,933 8,059 Bank of China (c) 1,544 1,612 China Merchants Bank (d) 3,087 - Industrial and Commercial Bank of China (d) - 3,223 China Construction Bank (e) 7,719 - Bank loans due within one year 19,914 17,729 China Construction Bank (f) - 13,861 China Construction Bank (g) - 4,044 Bank of Beijing (h) - 11,741 Beijing Zhongguancun Development Group (i) 1,861 - Current portion of long-term bank loans and other debt 1,861 29,646 Bank of Beijing (h) 756 - Beijing Zhongguancun Development Group (i) - 1,803 Long-term bank loans and other debt 756 1,803 Total bank loans and other debt $ 22,531 $ 49,178 (a) In 2014, Sinovac Beijing entered into a bank loan with China Merchants Bank in the aggregate principal amount of $ 4,835 30 15 6.9 In 2015 Sinovac Beijing entered into a new bank loan with China Merchants Bank in the aggregate principal amount of $ 4,631 30 15 5.58 (b) In 2014, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $ 8,059 50 6 On September 18, 2015, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $ 7,719 50 4.35 1,467 9.5 1,466 9.5 (c) On December 17, 2012, Sinovac Dalian entered into a bank loan agreement with Bank of China with a credit line of $ 3,223 20 7.44 806 5 806 5 806 5 806 5 On March 17, 2015, Sinovac Dalian entered into a bank loan with Bank of China in the aggregate principal amount of $ 772 5 30 6.955 772 5 6.01 8,892 57.6 (d) In 2014, Sinovac Beijing entered into a bank loan with Industrial and Commercial Bank of China in the aggregate principal amount of $ 3,223 20 10 7.5 64 0.4 5,641 35 On November 5, 2015, Sinovac Beijing entered into a one-year term bank loan with China Merchants Bank in the aggregate principal amount of $ 3,087 20 5 4.57 62 0.4 5,403 35 (e) On June 4, 2015, Sinovac Beijing entered into a bank loan with China Construction Bank in the aggregate principal amount of $ 7,719 50 5.36 16,229 105.1 (f) The loan from China Construction Bank in the aggregate principal amount of $ 13,894 90 6.4 17,798 110 322 2 322 2 13,861 86 (g) The total amount of the loan facility from China Construction Bank was $ 8,059 50 4,996 31 6.15 10 10 458 3 494 3 3,874 25 (h) The loan from Bank of Beijing in the aggregate principal amount of $ 23,531 146 32,234 200 6.4 11,790 72.6 11,741 72.9 3,285 20.4 On May 20, 2015, Sinovac Beijing entered into a new bank loan with Bank of Beijing in the aggregate principal amount of $ 7,410 48 5.25 756 4.9 2,896 18.8 (i) The Loan from Beijing Zhongguancun Development Group in the aggregate principal amount of $ 1,934 12 0.36 967 6 967 6 10.62 358 6.9 376 Within 1 year $ 21,775 More than 1 year 756 Total $ 22,531 The weighted average effective interest rate for all short-term and loan-term bank loans was 6.0 6.8 6.6 6.0 6.8 7.0 2,059 3,374 2,942 116

Related Party Transactions and

Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions and Balances (a) Loan from a non-controlling shareholder December 31, December 31, 2015 2014 Loan - current $ 2,470 $ 2,595 The Company has a loan due to Dalian Jin Gang Group, the non-controlling shareholder of Sinovac Dalian, which is unsecured, bearing interest at 7.2 183 221 237 16 199 4 237 (b) The Company entered into the following transactions in the normal course of operations at the exchange amount with related parties: For the year ended December 31, 2015 2014 2013 Rent expenses payable to SinoBioway Biotech Group Co. Ltd. (“SinoBioway”). $ 852 $ 869 $ 847 In 2004, the Company entered into two operating lease agreements with SinoBioway, the non-controlling shareholder of Sinovac Beijing, with respect to Sinovac Beijing’s production plant and laboratory in Beijing, China with annual lease payments totaling $ 220 1.4 20 One 81 0.5 220 1.4 In June 2007 325 2.0 2007 20 In September 2010, the Company entered into another operating lease agreement with SinoBioway with respect to expansion of Sinovac R&D’s business in research and development activities for an annual lease payment of $ 161 1.0 five On April 8, 2013, the Company entered into three four Included in current and long-term prepaid expenses and deposits as at December 31, 2015, is $ 377 2.4 389 2.4

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	13. Accounts Payable and Accrued Liabilities December 31, 2015 December 31, 2014 Trade payables $ 1,715 $ 3,033 Machinery and equipment payables 2,220 2,050 Accrued expenses 9,647 8,330 Value added tax payable 260 200 Other tax payable 183 171 Withholding tax payable 238 338 Bonus and benefit payables 5,231 5,626 Other payables 3,030 2,790 Total $ 22,524 $ 22,538

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes Antigua and Barbuda Under the current laws of Antigua and Barbuda, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to its shareholders, no Antigua and Barbuda withholding tax will be imposed. Hong Kong Under the Hong Kong tax laws, Sinovac Hong Kong is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. China Effective from January 1, 2008, the PRC’s statutory income tax rate is 25 25 3 15 For the year ended December 31, 2015 2014 2013 Non-PRC $ (2,802) $ (1,336) $ (65) PRC 5,833 3,982 9,476 Total $ 3,031 $ 2,646 $ 9,411 For the year ended December 31, 2015 2014 2013 Non-PRC $ - $ - $ - PRC (728) (1,524) (1,266) Total $ (728) $ (1,524) $ (1,266) Income taxes that are attributed to the discontinued operations in China were $nil for all the periods presented. For the year ended December 31, 2015 2014 2013 Continuing operations $ (2,516) $ (1,458) $ 2,225 Discontinued operations - - - Total $ (2,516) $ (1,458) $ 2,225 Income taxes are attributed to the continuing operations in China and consist of: For the year ended December 31, 2015 2014 2013 Current $ (3,034) $ (1,620) $ - Deferred 518 162 2,225 Total income tax benefit (expense) $ (2,516) $ (1,458) $ 2,225 The following is a reconciliation of the Company’s total income tax benefit (expense) to the amount computed by applying the PRC statutory income tax rate of 25 from continuing operations For the year ended December 31, 2015 2014 2013 Income from continuing operations before income taxes $ 3,031 $ 2,646 $ 9,411 Income tax expense at the PRC statutory rate (758) (662) (2,352) International tax rate differential (701) (334) (16) Super deduction for research and development expenses 463 605 332 Non-deductible expenses (900) (524) (159) Other adjustments 139 (89) 297 Effect of preferential tax rate 1,350 901 1,573 Change in valuation allowance (1,618) (1,249) 2,550 Effect of PRC withholding tax (89) (106) - Effect of prior years’ income tax arising from tax inspection (402) - - Income tax benefit (expense) $ (2,516) $ (1,458) $ 2,225 The tax effects of temporary differences from continuing operations that give rise to the Company’s deferred tax assets are as follows: December 31, 2015 2014 Accrued expenses $ 2,551 $ 2,410 Inventories 266 72 Prepaid expenses and deposits - (6) Deferred government grants 203 12 Less: valuation allowance (417) (222) Deferred tax assets, current portion $ 2,603 $ 2,266 Fixed assets 1,664 1,105 Deferred government grants 259 428 Tax losses carried forward 9,867 8,665 Less: valuation allowance (11,197) (9,683) Deferred tax assets, non-current portion $ 593 $ 515 In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible or utilized. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible or can be utilized, the Company provided valuation allowance of $ 11,614 9,905 The Company evaluates its valuation allowance requirements at end of each reporting period by reviewing all available evidence, both positive and negative, and considering whether, based on the weight of that evidence, a valuation allowance is needed. When circumstances cause a change in management’s judgement about the realizability of deferred tax assets, the impact of the change on the valuation allowance is generally reflected in income from operations. The future realization of the tax benefit of an existing deductible temporary difference ultimately depends on the existence of sufficient taxable income of the appropriate character within the carryforward period available under applicable tax law. Tax losses of the Company’s PRC subsidiaries in the amount of $ 39,466 238 will expire from 2016 to 2020. As of December 31, 2015, the Company has not recognized any deferred tax liability on Sinovac Beijing’s undistributed earnings of approximately $ 10,733 5 10 537 1,073 The changes in unrecognized tax benefits are as follows: For the year ended December 31, 2015 2014 2013 Balance at January 1 454 350 335 Additions for tax positions of the current year 159 160 15 Additions for tax positions of the prior years 281 - - Settlement with the taxing authority (103) - - Lapse of statute of limitations (35) (56) - Balance at December 31 $ 756 $ 454 $ 350 The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as part of its income tax expenses. The Company did not record any interest and penalties for the periods presented. The PRC tax law provides statute of limitations ranging from 3 5 10 As of December 31, 2015, the Company had unrecognized tax benefits of approximately $ 756 454 350 As December 31, 2015, amounting to $ 607 (December 31, 2014 - $ 454 350 397 of the related open tax years expenses 281

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue Disclosure [Text Block]	15. Deferred Revenue Current deferred revenue included $ 6,549 3,546 1,595 1,450 No long-term deferred revenue was received from the Chinese government for stockpiling of H5N1 vaccines as of December 31, 20 15 (Decemb er 31, 2014 -$ 7,191

Deferred Government Grants

Deferred Government Grants	12 Months Ended
	Dec. 31, 2015
Deferred Government Grant [Abstract]
Deferred Government Grant Disclosure [Text Block]	16. Deferred Government Grants Deferred government grants represent funding received from the government for research and development (“R&D”), or investment in building or improving production facility. The amount of deferred government grants as at year end is net of research and development expenditures or depreciation incurred or those recognized as government grant income. The Company received $ 236 1.5 3,496 21.6 842 5.2 308 1.9 24 0.1 December 31, December 31, 2015 2014 Construction of a pandemic influenza vaccine plant and buildings (a) $ 278 $ 290 Purchasing equipment for H1N1 vaccine production (b) 137 143 Purchasing equipment for H5N1 vaccine production (c) 15 16 EV71 vaccine production facility (d) 259 - Research and development for EV71 (e) 77 - Loan from Zhongguancun Development Group (f) 358 - Others (g) 78 81 Current deferred government grants 1,202 530 Construction of a pandemic influenza vaccine plant and buildings (a) 848 1,176 Purchasing equipment for H1N1 vaccine production (b) 330 488 Purchasing equipment for H5N1 vaccine production (c) 46 64 EV71 vaccine production facility (d) 2,828 3,223 Research and development for EV71 (e) - 1,524 Loan from Zhongguancun Development Group (f) - 376 Others (g) 678 643 Non-current deferred government grants 4,730 7,494 Total deferred government grants $ 5,932 $ 8,024 (a) Deferred government grants included $ 1,126 7.3 20 1,466 9.1 278 1.8 848 5.5 287 290 237 (b) Deferred government grants also included $ 467 3.0 999 6.2 137 (RMB 0.8 330 2.2 141 143 119 (c) Deferred government grants also included $ 61 0.4 15 0.1 46 0.3 16 16 16 (d) The Company received a government grant in the amount of $ 3,087 20 259 1.7 2,828 18.3 (e) Deferred government grants also included $ 77 0.5 1,598 10 (f) The Company received a loan of $ 1,934 12 0.36 6.9 358 376 (g) Deferred government grants also included $ 756 4.9 678 4.4 642 4 78 0.5 81 0.5

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	17 Commitments and Contingencies (a) Operating Lease Commitments The Company leases production plant and laboratory under operating leases from its related parties (note 12(b)). Rental expense amounted to $ 852 869 847 2016 $ 852 2017 852 2018 852 2019 852 2020 852 Thereafter 8,601 Total minimum future payments $ 12,861 (b) Other Commitments In addition to commitments disclosed in note 24, commitments related to R&D expenditures are $ 441 Commitments related to capital expenditures for the Company’s Sabin Inactivated Polio vaccine, pneumococcal polysaccharide vaccine and varicella vaccine production facilities are approximately $ 1,726

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Common Stock [Text Block]	18. Common Stock Share Capital Each share of common stock is entitled to one vote per share and is entitled to dividends when declared by the Company’s board of directors. As of December 31, 2015 and 2014, there were 56,906,561 55,809,661 In 2013, the Company issued 360,600 1.60 118,200 2.37 848 18 In 2014, the Company issued 48,000 1.60 191,300 2.37 512 51 In 2015, the Company issued 115,500 1.60 252,400 2.37 732 18 In May 2015, the Company granted 729,000 0.001 1

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	19. Stock Options (a) Stock Option Plan The board of directors approved a stock option plan (the “2003 Plan”) effective on November 1, 2003, pursuant to which directors, officers, employees and consultants of the Company are eligible to receive grants of options for the Company’s common stock. The 2003 Plan expires on November 1, 2023. Up to 10 42,800 10 In December 2011, the Company granted 767,000 2.37 10 On May 1, 2012, the Company granted 50,000 2.05 10 10 27 On August 22, 2012, the board of directors approved a new stock option plan (the “2012 Plan”), which allowed the Company to issue up to 4,000,000 10 On May 1, 2015, the Company granted 729,000 0.001 1,341,000 4.98 April 30, 2023 (b) Valuation Assumptions The following assumptions were used in determining the fair value of stock options under the Black-Scholes option-pricing model for grants under the 2012 Plan: 2015 2014 2013 Expected volatility 51.42 % - - Risk-free interest rate 1.5 % - - Expected life (years) 5.5 - - Dividend yield 0 % - - Estimated forfeiture rate 7 % - - The weighted average fair value of options granted for the year ended December 31, 2015 was $ 2.37 Expected volatility is estimated based on the Company’s historical stock prices. Computation of expected life was estimated using simplified method for “plain-vanilla” options as the Company considers the options granted to have “plain-vanilla” characteristics. The risk-free interest rates for the period within the contractual life of the awards are based on the U.S. Treasury yield in effect at the time of grant. Estimated forfeiture rates are determined based on expected future employee behaviour. The fair value of restricted shares is based on the fair market value of the underlying common stock on the date of the grant. (c) Stock-based Payment Award Activity A summary of the Company’s stock options activity for the 2003 and 2012 Plan is presented below: Weighted Average Aggregate Intrinsic Number Exercise Price Value of Options ($/option) ($) Outstanding as at January 1, 2015 637,200 $ 2.09 $ 1,997,644 Granted 1,341,000 4.98 - Exercised (367,900) 2.13 - Forfeited / Expired (129,900) 1.71 - Outstanding as at December 31, 2015 1,480,400 $ 4.73 $ 1,459,330 Vested and expected to vest at December 31, 2015 1,386,530 $ 4.72 $ 1,389,866 Exercisable as at December 31, 2015 139,400 $ 2.37 $ 466,990 Number Weighted Average Non-vested as at January 1, 2015 — $ — Granted 729,000 4.98 Vested — — Forfeited / Expired — — Non-vested as at December 31, 2015 729,000 $ 4.98 As at December 31,2015 Number Number of Remaining Average Average of Remaining Exercise Options Contractual Exercise Options Contractual Average Exercise Prices Outstanding Life (years) Price Exercisable Life (years) Price ($/option) ($/option) ($/option) $ 2.37 139,400 1.99 $ 2.37 139,400 1.99 $ 2.37 $ 4.98 1,341,000 7.33 $ 4.98 - - - 1,480,400 6.83 139,400 1.99 $ 2.37 Stock-based compensation expense, included in cost of sales, selling, general and administrative expenses, and R&D expenses is charged to operations over the vesting period of the options using the straight-line amortization method. The share-based compensation expense was $ 952 287 281 2,557 2,921 52 The aggregate intrinsic value of the Company’s stock options is calculated as the difference between the exercise price of the options and the quoted price of the common shares that were in the money. The aggregate intrinsic value of the Company’s stock options exercised under the 2003 Plan was $ 1,118 840 1,344 The estimated fair value of stock options vested during the year ended December 31, 2015 was $ 104 414 420

Statutory surplus reserves

Statutory surplus reserves	12 Months Ended
	Dec. 31, 2015
Distribution Of Profit Disclosure [Abstract]
Distribution Of Profit Disclosure [Text Block]	20 . Statutory surplus reserves Pursuant to Chinese company law applicable to foreign investment companies, the Company’s PRC subsidiaries are required to maintain statutory surplus reserves. The statutory surplus reserves are to be appropriated from net income after taxes, and should be at least 10 50 13,450 12,627 For the year ended December 31, 2015, Sinovac Beijing appropriated 10% 10 0 823 5.2 819 Pursuant to the same Chinese company law, the Company’s subsidiaries, Sinovac Beijing, Tangshan Yian, Sinovac R&D, Sinovac Dalian and Sinovac Biomed can transfer, at the discretion of their respective boards of directors, a certain amount of their annual net income after taxes as determined under PRC GAAP to a staff welfare and bonus fund which shall be utilized for collective staff benefits. For the year ended December 31, 2015, the amount is $nil for contribution to such fund (2014 - $nil, 2013 - $nil). The amounts appropriated to the staff welfare and bonus fund were charged against income and the related provisions were reflected as accrued liabilities in the consolidated balance sheets. Tangshan Yian recorded a net loss for each of the three years in the period ended December 31, 2015, so no appropriation to the statutory surplus reserves and staff welfare and bonus fund was made. Sinovac R&D, Sinovac Dalian and Sionvac Biomed were Dividends declared by the Company’s PRC subsidiaries are based on the distributable profits as reported in their statutory financial statements reported in accordance with PRC GAAP, which differ from the results of operations reflected in the consolidated financial statements prepared in accordance with US GAAP. The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its PRC subsidiaries. Dividends declared in 2015 was $nil to the non-controlling shareholder of Sinovac Beijing (2014 - $nil, 2013 - $nil). As of December 31, 2015, the Company has $nil dividend payable (December 31, 2014 - $nil). Under PRC laws and regulations, statutory surplus reserves are restricted to set-off against losses, expansion of production and operation and increasing registered capital of the respective company, and are not distributable other than upon liquidation. Staff welfare and bonus funds are restricted to expenditures for the collective welfare of employees. The reserves are not allowed to be transferred to the Company in terms of cash dividends, loans or advances, nor are they allowed for distribution except under liquidation. Amounts restricted include the PRC subsidiaries’ paid-in capital and statutory surplus reserves of the Company’s PRC subsidiaries totalling $ 77,511 502 80,091 497 66,590 61,345

Non-controlling Interests

Non-controlling Interests	12 Months Ended
	Dec. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	21. Non-controlling Interests Non-controlling interests represent the interest of non-controlling shareholders in Sinovac Beijing and Sinovac Dalian based on their proportionate interests in the equity of that company adjusted for its proportionate share of income or losses from operations. On October 1, 2011, the Company increased its ownership in Sinovac Beijing by an additional 1.53 2,998 18.6 258 1.6 28.44 26.91 26.91 45

Earnings (loss) per Share

Earnings (loss) per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	22. Earnings (loss) per Share For the year ended December 31 2015 2014 2013 Numerator Income (loss) from continuing operations 515 1,188 11,636 Less: Income (loss) attributable to non-controlling interests 861 515 2,928 Income (loss) attributable to shareholders of Sinovac from continuing operations (346) 673 8,708 Income (loss) attributable to shareholders of Sinovac from discontinued operations (728) (1,524) (1,266) Net income (loss) attributable to shareholders of Sinovac (1,074) (851) 7,442 Denominator Basic weighted average number of common shares outstanding 56,313,927 55,681,076 55,301,276 Dilutive effect of stock options - 433,126 501,062 Diluted weighted average number of common shares outstanding 56,313,927 56,114,202 55,802,338 Basic net income (loss) per share Continuing operations (0.01) 0.01 0.15 Discontinued operations (0.01) (0.03) (0.02) Basic net income (loss) per share (0.02) (0.02) 0.13 Diluted net income (loss) per share Continuing operations (0.01) 0.01 0.15 Discontinued operations (0.01) (0.03) (0.02) Diluted net income (loss) per share (0.02) (0.02) 0.13 Anti-dilutive options were not included in the diluted EPS calculation for the year ended December 31, 2015. Anti-dilutive non-vested restricted shares were not included in the diluted EPS calculation for the year ended December 31, 2015.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	23. Segment Information The Company operates exclusively in the biotechnology sector. The Company’s business is considered as operating in one segment. The Company’s Chief Executive Officer is the chief operating decision maker and reviews the consolidated results of operations when making decisions about resources allocation and assessing performance of the Company as a whole. All revenues are generated from the subsidiaries located in China. Total long-lived assets of $ 73,514 76,846 December 31, 2015 December 31, 2014 Assets Mainland China $ 173,629 $ 207,645 Hong Kong 29,355 30,885 Total $ 202,984 $ 238,530 For the year ended December 31, 2015 2014 2013 Sales Inactivated hepatitis vaccines $ 49,416 $ 48,450 $ 47,202 Influenza vaccines 12,674 12,131 12,156 H5N1 3,852 201 10,736 Mumps 1,472 2,150 1,680 Total $ 67,414 $ 62,932 $ 71,774 For the year ended December 31, 2015, one of the Company’s customer accounted for 14 9,128 For the year ended December 31, 2015 2014 2013 Sales Mainland China $ 66,779 $ 61,955 $ 70,647 Foreign countries 635 977 1,127 Total $ 67,414 $ 62,932 $ 71,774

Collaboration Agreements

Collaboration Agreements	12 Months Ended
	Dec. 31, 2015
Collaboration Agreements Disclosure [Abstract]
Collaborative Arrangement Disclosure [Text Block]	24. Collaboration Agreements (a) On March 12, 2009, the Company entered into a technology transfer agreement (with an amendment agreement entered on December 14, 2011) with Tianjin CanSino Biotechnology Inc. (“Tianjin Cansino”). According to the agreement, Tianjing Cansino will transfer the technology related to pneumococcal vaccine to the Company and jointly develop the technology with the Company. The collaboration term under the technology transfer agreement is from March 12, 2009 to eight Under the terms of the technology transfer agreement, the Company will make milestone payments of up to $ 3,000 6 10 300 1,200 1,000 200 On January 29, 2015, the Company entered into a third amendment to the technology transfer agreement dated March 12, 2009 and the two amendment agreements dated November 17, 2009 and December 24, 2011. By entering into this third amendment, the technology transfer agreement was revised to be a licensing agreement. The remaining milestone and royalty payments under the technology transfer agreement have been reduced. Both the Company and Tianjin Cansino are free to develop pneumococcal vaccines or to collaborate with one other company for the same purpose. The Company made a payment of $ 300 (b) On August 18, 2009, the Company entered into a patent license agreement with the National Institutes of Health (“NIH”), an agency of the United States Public Health Services within the Department of Health and Human Services. NIH has granted the Company a non-exclusive license to make and use certain of its products. NIH has also granted the Company the right to use certain associated information for development of its licensed products. The collaboration term under the patent license agreement is from August 18, 2009 to the later of (a) the expiration of all royalty obligations under the licensed rights where such rights exist and (b) eight The Company has agreed to pay NIH a license issue royalty of $ 80 8 1.5 4 330 9 8 21 (c) On August 15, 2011, the Company licensed from Medimmune, LLC, a US based pharmaceutical company, certain non-exclusive rights to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. The Company has agreed to pay an upfront license fee and milestone payments of up to an aggregate of $ 9.9 3,400 3 1,036 On August 15, 2012, the Company entered into amendment agreements with Medimmune to revise the termination date of the license to December 29, 2015 as a result of amendment of the main license agreement to end on December 29, 2015. (d) On April 3, 2014, the Company entered into a non-exclusive license agreement (the “Agreement”) with The Institute for Translational Vaccinology (“INTRAVACC”), a governmental institute working under the Dutch Ministry of Public Health, Welfare and Sports, to develop and commercialize the Sabin Inactivated Polio Vaccine (“sIPV”) for distribution in China and other countries. The Company expects to develop and commercialize the vaccine in China, as well as seeking regulatory approval in other countries. The agreement has a term of 50 The Company has agreed to pay INTRAVACC up to $ 2,406 1.5 665 0.5 125 94 (e) In September 2015, Sinovac Dalian entered into a technology transfer and supply agreement with GlaxoSmithKline Biologicals SA, or GSK, to use GSK’s measles seeds to develop combination vaccines containing measles for the China market. Under this agreement, GSK agreed to transfer its measles seeds, provide reasonable assistance and relevant technical materials to Sinovac Dalian for the purpose of developing and producing combination vaccines containing measles.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	25. Subsequent Events In February 2016, the Company completed the disposal of Tangshan Yian. In March 2016, the Company adopted a shareholder rights plan (the “Rights Plan”). Pursuant to the Rights Plan, subject to limited exceptions, upon (i) a person or group obtaining ownership of 15% or more of the Company’s common shares or (ii) the commencement or announcement of an intention to make a tender offer or exchange offer, the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the Company’s common shares, in each case, without the approval of the Company’s board of directors, each Right will entitle the holders, other than the acquiring person, to buy, at an exercise price of $30.00, one one-thousandth of a share of the newly created series A junior participating preferred shares of the Company, or the Series A Preferred Shares. Holders are entitled to receive, in lieu of each one one-thousandths of a Series A Preferred Share, common shares having a market value at that time of twice the Right’s exercise price. The Company’s board of directors is entitled to redeem the Rights at $0.001 per Right at any time before the Rights are exercisable. The Company refers to the person who acquired 15% or more of the outstanding common shares of the Company as the “acquiring person.”

Condensed Financial Information

Condensed Financial Information of the Parent Company	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Financial Information of Parent Company Only Disclosure [Text Block]	26. Condensed Financial Information of the Parent Company Balance Sheets December 31, December 31, 2015 2014 ASSETS Current assets Cash and cash equivalents $ 331 $ 997 Prepaid expenses and other receivables 70 9 Amount due from subsidiaries 66,032 69,824 Dividend receivables 21,280 21,280 Total current assets 87,713 92,110 Investment in subsidiaries 41,711 38,616 Total assets $ 129,424 $ 130,726 LIABILITIES AND EQUITY Current liabilities Accrued expenses and other payables $ 666 $ 584 Amount due to subsidiaries 5,478 3,578 Total current liabilities 6,144 4,162 Total liabilities $ 6,144 $ 4,162 EQUITY Preferred stock - - Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil Common stock 57 56 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 56,906,561 (2014 – 55,809,661) Additional paid-in capital 109,944 108,243 Accumulated other comprehensive income 8,110 12,022 Retained earnings 5,169 6,243 Total stockholders' equity 123,280 126,564 Total liabilities and equity $ 129,424 $ 130,726 Statements of Comprehensive Income (Loss) For the year ended December 31 2015 2014 2013 Selling, general and administrative expenses 2,563 2,466 2,710 Total operating expenses 2,563 2,466 2,710 Loss from operations (2,563) (2,466) (2,710) Other expense (5,053) - - Interest income 413 759 755 Equity earnings of subsidiaries, net of tax 6,129 856 9,397 Net income (loss) (1,074) (851) 7,442 Other comprehensive income (loss), net of tax of nil - - - Foreign currency translation adjustments (3,912) (2,119) 2,370 Total comprehensive income (loss) $ (4,986) $ (2,970) $ 9,812 Statements of Cash Flows For the year ended December 31 2015 2014 2013 Cash flows provided by (used in) operating activities Net income (loss) $ (1,074) $ (851) $ 7,442 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: -stock-based compensation 952 287 281 -equity in (earnings) of subsidiaries (6,129) (856) (9,397) Changes in: - Amount due from subsidiaries 3,792 (1,304) 2,505 - Prepaid expenses and other receivables (61) 114 59 - Dividend receivables - - 1,043 - Amount due to subsidiaries 1,900 1,815 1,130 - Accrued expenses and other payables 82 (336) (776) Net cash provided by (used in) operating activities (538) (1,131) 2,287 Cash flows provided by financing activities - Proceeds from issuance of common stock, net of share issuance costs 732 512 848 - Proceeds from shares subscribed 18 51 18 Net cash provided by financing activities 750 563 866 Cash flows provided by (used in) investing activities -Investment in subsidiaries (878) 165 (4,042) Net cash provided (used in) investing activities (878) 165 (4,042) Decrease in cash and cash equivalents (666) (403) (889) Cash and cash equivalents, beginning of year 997 1,400 2,289 Cash and cash equivalents, end of year $ 331 $ 997 $ 1,400 (a) Basis of presentation The condensed financial information has been prepared using the same accounting policies as set out in the accompanying consolidated financial statements except that the Company used the equity method to account for investment in its subsidiaries. The Company records its investment in its subsidiaries under the equity method of accounting. Such investment is presented on the balance sheets as “Investment in subsidiaries” and share of their income (loss) as “Equity earnings (losses) of subsidiaries” in the statements of comprehensive income (loss). Each of the Company’s PRC subsidiaries has restrictions on its ability to pay dividends to the Company under PRC laws and regulations (Note 20). The subsidiaries did not pay any dividends to the Company for the years presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted by reference to the consolidated financial statements. (b) Commitments The Company does not have any significant commitments or long-term obligations as of any of the periods presented, except for those disclosed in the consolidated financial statements (notes 17 and 24).

Significant Accounting Polici34

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	(a) Use of Estimates In preparation of the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates made by management include: provision for product returns, allowance for doubtful accounts, inventory provisions, useful lives of amortizable intangible assets, impairment of long-lived assets, fair value of options granted and related forfeiture rates, and realizability of deferred tax assets. On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s consolidated financial statements could be materially impacted
Cash and Cash Equivalents, Policy [Policy Text Block]	(b) Cash and Cash Equivalents Cash equivalents consist of highly liquid investments that are readily convertible to cash generally with maturities of three months or less when purchased.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	(c) Restricted Cash Restricted cash is cash held as collateral for transactions the Company has entered into. As of December 31, 2015, the balance of $ 1,626
Trade and Other Accounts Receivable, Policy [Policy Text Block]	(d) Accounts Receivable The Company extends unsecured credit to its customers in the ordinary course of business and actively pursues past due accounts. The Company estimates an allowance for doubtful accounts based on historical experience, the age of the accounts receivable balances, credit quality of the Company’s customers, current economic conditions and other factors that may affect its customers’ ability to pay.
Inventory, Policy [Policy Text Block]	(e) Inventories Prior to January 1, 2015, inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost or market with respect to finished goods and work in progress. The Financial Accounting Standards Board (“
Property, Plant and Equipment, Policy [Policy Text Block]	(f) Property, Plant and Equipment Property, plant and equipment are recorded at cost. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expenses as incurred. Equipment purchased for specific research and development projects with no alternative uses are expensed. Assets under construction are not depreciated until construction is completed and the assets are ready for their intended use. Gains and losses from the disposal of property, plant and equipment are recorded in loss on disposal and impairment of property, plant and equipment included in the consolidated statements of comprehensive income (loss). Depreciation of property, plant and equipment is computed using the straight-line method based on the estimated useful lives of the assets as follows: Plant and buildings 10 to 24 years Machinery and equipment 8 to 10 years Motor vehicles 4 to 5 years Office equipment and furniture 3 to 5 years Leasehold improvements Lesser of useful lives and term of lease
Prepaid Land Lease Payments [Policy Text Block]	(g) Prepaid Prepaid land lease payments represent amounts paid for the rights to use land in the PRC and is recorded at purchased cost less accumulated amortization. Amortization is provided on a straight-line basis over the term of the lease agreement, which is 28 49
Licenses [Policy Text Block]	(h) Licenses The Company capitalizes the patent payment and the purchased cost of vaccines if the vaccine has received a new drug certificate from the China Food and Drug Administration (“CFDA”) of China. If the vaccine has not received a new drug certificate, the purchase cost is expensed as in-process research and development. Licenses in relation to the production and sales of pharmaceutical products are amortized on a straight-line basis over their respective useful lives. The useful lives of inactivated hepatitis A and recombinant hepatitis A&B licenses are estimated to be ten years. Before August 15, 2012, the useful life for H5N1 licenses was estimated to be 20 9.16
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	(i) Impairment of Long-Lived Assets Long-lived assets including intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset group may not be recoverable from the future undiscounted net cash flows expected to be generated by the asset group. An asset group is identified as assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets. If the asset group is not fully recoverable, an impairment loss would be recognized for the difference between the carrying value of the asset group and its estimated fair value, based on the discounted net future cash flows or other appropriate methods, such as comparable market values. The Company uses estimates and judgments in its impairment tests and if different estimates or judgment had been utilized, the timing or the amount of any impairment charges could be materially different. The Company recorded impairment charges on long-lived assets for the year ended December 31, 2015 of $nil (2014 - $nil, 2013 - $ 57
Income Tax, Policy [Policy Text Block]	(j) Income Taxes The Company follows the liability method of accounting for income taxes. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the carrying values and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such a position are measured based on the amount that is greater than 50% likely of being realized upon settlement. The Company recognizes a change in available facts after the reporting date but before issuance of the financial statements in the period when the change in facts occur, even if that new information provides a better estimate of the ultimate outcome of an uncertainty. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.
Value Added Taxes [Policy Text Block]	Value-added Taxes Value-added taxes (“VAT”) collected from customers relating to product sales and remitted to governmental authorities are presented on a net basis. VAT collected from customers is excluded from revenue. Prior to July 1, 2014, the Company was subject to a VAT rate of 6 3
Revenue Recognition, Policy [Policy Text Block]	(l) Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. The Company generally obtains purchase authorizations from its customers for a specified amount of products at a specified price and considers delivery to have occurred when the customer takes title of the products. The Company provides certain customers with a right of return. Revenue for inactivated hepatitis A, combined inactivated hepatitis A&B and seasonal influenza vaccines are recognized when delivery has occurred and the Company estimates return provision for these products. The product return provisions for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine are estimated based on historical return and exchange levels as well as the inventory levels and the remaining shelf lives of the products in the distribution channels. As of December 31, 2015, the sales return provision for inactivated hepatitis A vaccine and combined inactivated hepatitis A&B vaccine was $ 5,900 3,553 13.6 8.6 1,462 1,320 Revenue for animal and mumps vaccines without a right of return provided to customers is recognized when delivery has occurred. Revenue for animal and mumps vaccines with a right of return provided to customers is recognized when payments are collected from customers as the Company currently does not have sufficient historical data to estimate returns for these products. Deferred revenue is generally related to government stockpiling programs and advances received from customers. For government stockpiling programs of H5N1 vaccines, the Company generally obtains purchase authorizations from the government for a specified amount of products at a specified price and no rights of return are provided. Revenue is recognized when the government takes delivery of the products. If the products expire prior to delivery, these expired products are recognized as revenue once cash is received and the products have expired and passed government inspection.
Shipping and Handling Cost, Policy [Policy Text Block]	(m) Shipping and Handling Shipping and handling fees billed to customers are included in sales. Costs related to shipping and handling are recognized in selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). For the year ended December 31, 2015, $ 1,389 1,235 1,215
Advertising Costs, Policy [Policy Text Block]	(n) Advertising Expenses Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $ 851 268 474
Research and Development Expense, Policy [Policy Text Block]	(o) Research and Development Research and development ("R&D") costs are expensed as incurred and are disclosed as a separate line item in the Company’s consolidated statements of comprehensive income (loss). R&D costs consist primarily of the remuneration of R&D staff, depreciation, material, clinical trial costs as well as amortization of acquired technology and know-how used in R&D with alternative future uses. R&D costs also include costs associated with collaborative R&D and in-licensing arrangements, including upfront fees paid to collaboration partners in connection with technologies which have not reached technological feasibility and did not have an alternative future use. Reimbursement of R&D costs for arrangements with collaboration partners is recognized when the obligations are incurred. Under certain R&D arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific development, regulatory and/or commercial milestones. Before a product receives regulatory approval, license fees and milestone payments made to third parties are expensed as incurred. License fees and milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the remaining life of the agreement with third parties.
Government Contractors, Revenue Recognition, Policy [Policy Text Block]	(p) Government Grants Government grants received from the PRC government by the PRC operating subsidiaries of the Company are recognized when there is reasonable assurance that the amount is receivable and all the conditions specified in the grant have been met. Government grants for R&D are recognized as a reduction to R&D expenses when the expenses are incurred in the same period when the conditions attached to the grants are met, or recognized as government grants recognized in income in the period when the conditions are met after the expenses are incurred. Government grants for property, plant and equipment are deferred and recognized as a reduction to the related depreciation and amortization expenses in the same manner as the property, plant and equipment are depreciated. Interest subsidies are recorded as a reduction to interest and financing expenses in the consolidated statements of comprehensive income (loss), or recorded as a reduction to interest capitalized if the subsidies granted are related to a specific borrowing associated with building a qualifying asset. For government loans received at below market interest rate, the difference between the face value of the loan and fair value using the effective interest rate method is recorded as deferred government grants. Accretion expense is recorded in interest and financing expense and the government grant will be recognized as “government grants recognized in income” in the consolidated statement of comprehensive income (loss) when the government loan is fully repaid.
Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]	(q) Retirement and Other Post-retirement Benefits Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company makes contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no legal obligation for the benefits beyond the contributions. The total amounts for such employee benefits, which were expensed as incurred was $ 3,577 3,338 3,083
Foreign Currency Transactions and Translations Policy [Policy Text Block]	(r) Foreign Currency Translation and Transactions The Company maintains their accounting records in their functional currencies, U.S. dollars (“US$”) for the Company and Sinovac Hong Kong and Renminbi Yuan (“RMB”) for the PRC subsidiaries. The Company uses the US$ as its reporting currency. At the transaction date, each asset, liability, revenue and expense is re-measured into the functional currency by the use of the exchange rate in effect at that date. At each period end, foreign currency monetary assets, and liabilities are re-measured into the functional currency by using the exchange rate in effect at the balance sheet date. The resulting foreign exchange gains and losses are included in selling, general and administrative expenses. The Company recognized foreign exchange gains (losses) of $ (886) (619) 650 The assets and liabilities of the PRC subsidiaries, Sinovac Beijing, Tangshan Yian, Sinovac R&D, Sinovac Dalian and Sinovac Bitomed are translated into US$ at the exchange rates in effect at the balance sheet date. Revenue and expenses are translated at average exchange rates. Gains and losses from such translations are recorded in accumulated other comprehensive income, a component of shareholders’ equity. Gains and losses on intra-entity foreign currency transactions that are of a long-term-investment nature was $ 560 294 235
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	(s) Stock-based Compensation Compensation expense for costs related to all share-based payments, including grants of stock options, is recognized through a fair-value based method. The Company uses the Black-Scholes option-pricing model to determine the grant date fair value for stock options. The Company uses the grant date stock price to determine the grant date fair value of restricted shares. The Company has elected to recognize share-based compensation costs using the straight-line method over the requisite service period with a graded vesting schedule, provided that the amount of compensation costs recognized at any date is at least equal to the portion of the grant date value of the awards that are vested at that date. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share based compensation costs are recorded net of estimated forfeitures such that expense is recorded only for those awards that are expected to vest.
Comprehensive Income, Policy [Policy Text Block]	(t) Comprehensive Income (loss) The Company’s comprehensive income (loss) consists of net income (loss) and foreign currency translation adjustments.
Earnings Per Share, Policy [Policy Text Block]	(u) Earnings (loss) Per Share Earnings (loss) per share is calculated in accordance with Accounting Standards Codification (“ Earnings per Share
Lease, Policy [Policy Text Block]	(v) Operating Leases Leases are classified as capital and operating depending on the terms and conditions of the lease agreement. Leases that transfer substantially all the benefits and risks incidental to ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases where rental payments are expensed as incurred. There are no capital leases for the periods presented.
Fair Value of Financial Instruments, Policy [Policy Text Block]	(w) Fair Value Measurements Assets and liabilities subject to fair value measurements are required to be disclosed within a specified fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: ⋅ Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. ⋅ Level 2 — Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active. ⋅ Level 3 — Unobservable inputs for the asset or liability. As of December 31, 2015 and 2014, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis. The carrying values of cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities and short-term bank loans and the current portion of long-term debt approximate their fair value because of their short-term nature. The fair values of long-term bank loans and other debt are estimated based on the discounted value of future contractual cash flows which approximates their carrying value due to the fact they are predominately stated at variable rates based on the People’s Bank of China. Fair value of the long-term bank loans and other debt are determined based on level 2 inputs. The Company measures property, plant and equipment at fair value on a non-recurring basis only if an impairment charge were to be recognized. There were no non-recurring fair value measurements for the years ended December 31, 2015 and 2014.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Risks The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between the US$ and the RMB. In 2015, foreign exchange gains (losses) of $(886) is included in selling, general and administrative expenses (2014- $(619), 2013 - $650). As at December 31, 2015, cash and cash equivalents of $ 46,923 304 71,968 447 Substantially all of the Company’s operating activities are transacted in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with other information such as suppliers’ invoices, shipping documents and signed contracts. Financial instruments that potentially subject the Company to concentration of credit risks consist primarily of cash and cash equivalents, restricted cash and accounts receivable, the balances of which are stated on the consolidated balance sheets which represent the Company’s maximum exposure. The Company places its cash and cash equivalents and restricted cash in good credit quality financial institutions in Hong Kong and China. Concentration of credit risks with respect to accounts receivables is linked to the concentration of revenue. The Company’s customers are mainly various government agencies in China. For the year ended December 31, 2015, one of the Company’s customers accounted for 14 The Company is subject to interest rate risk. Other than a loan with carrying value of $ 1,861 2,470
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards In August 2014, the FASB issued ASU No. 2014-15 (“ASU 2014-15”), Going Concern. Management of the Company will be required to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. The Company will adopt ASU 2014-15 on January 1, 2017, and does not expect the adoption of this standard will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). The guidance would require that debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of debt liability, consistent with debt discounts or premiums, rather than an asset. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early adoption is permitted. The Company is currently evaluating the impact, if any, of the adoption of ASU 2015-03 on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17 (“ASU 2015-17”), Income Taxes. To simplify the presentation of deferred income taxes, ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position, applicable to all entities that present a classified statement of financial position. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. While the Company is still assessing the impact on its consolidated financial statements of adopting this standard, it does not believe that the adoption of this guidance will have a material impact on its consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments. ASU 2016-01 requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements. That presentation provides financial statement users with more decision-useful information about an entity’s involvement in financial instruments. The guidance is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard. In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases. ASU 2016-02 requires recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. The guidance is effective for annual periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard. In March 2016, the FASB issued ASU No. 2016-09 (“ASU 2016-09”), Compensation – Stock Compensation. Under ASU 2016-09, the Company can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur. The guidance is effective for annual periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact on its consolidated financial statements of adopting this standard.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investments in and Advances to Affiliates [Table Text Block]	Place of incorporation Percentage of Date of (or ownership as Percentage of incorporation or establishment) of December ownership as of Name establishment /operation 31, 2015 December 31, 2014 Principal activities Sinovac Biotech (Hong Kong) Ltd. (“Sinovac Hong Kong”) October 2008 Hong Kong 100% 100% Investment holding company Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) (note 21) April 2001 People’s Republic of China (“PRC”) 73.09% 73.09% Research and development, production and sales of vaccine products Tangshan Yian Biological Engineering Co., Ltd. (“Tangshan Yian”) February 1993 PRC 100% 100% Research and development, production and sales of vaccine products Sinovac Biological Technology Co., Ltd. (“Sinovac R&D”) May 2009 PRC 100% 100% Research and development of vaccine products Sinovac (Dalian) Vaccine Technology Co., Ltd. (“Sinovac Dalian”) (note 21) January 2010 PRC 55% 55% Research and development, production and sales of vaccine products Sinovac Bitomed Co., Ltd. April 2015 PRC 100% - Distribution of vaccine products

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	Results of the discontinued operations are summarized as follows: For the year ended December 31, 2015 2014 2013 Sales $ 112 $ 169 $ 750 Cost of sales 406 1,017 768 Gross loss (294) (848) (18) Selling, general and administrative expenses 459 621 927 Research and development expenses 22 100 256 Total operating expenses 481 721 1,183 Operating (loss) (775) (1,569) (1,201) Other income (expense) 47 45 (65) (Loss) before income taxes (728) (1,524) (1,266) Income tax benefit (expense) - - - (Loss) from discontinued operations, net of income tax $ (728) $ (1,524) $ (1,266) The following table summarizes the carrying amounts of the major classes of assets and liabilities held for sale in the consolidated balance sheets as of December 31, 2015 and 2014, respectively: December 31, December 31, 2015 2014 Cash and cash equivalents $ 143 $ 225 Prepaid land lease payments 128 144 Property, plant and equipment 1,450 2,184 Other assets held for sale 76 162 Total assets held for sale 1,797 2,715 Accounts payable and accrued liabilities 217 699 Other liabilities held for sale 26 28 Total liabilities held for sale $ 243 $ 727

Restricted Cash (Tables)

Restricted Cash (Tables)	12 Months Ended
	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Schedule of Restricted Cash and Cash Equivalents [Table Text Block]	As of December 31, 2015, the balance of $ 1,626 December 31, December 31, 2015 2014 Restricted Cash $ 1,626 $ -

Accounts Receivable - net (Tabl

Accounts Receivable - net (Tables)	12 Months Ended
	Dec. 31, 2015
Loans and Leases Receivable Disclosure [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, December 31, 2015 2014 Trade receivables (note 11) $ 40,733 $ 42,423 Allowance for doubtful accounts (2,415) (2,571) 38,318 39,852 Other receivables 703 867 Total accounts receivable $ 39,021 $ 40,719
Accounts Receivable Aging [Table Text Block]	December 31, December 31, 2015 2014 Aging within one year, net of allowance for doubtful accounts $ 34,495 $ 35,130 Aging greater than one year, net of allowance for doubtful accounts 3,823 4,722 Total trade receivables $ 38,318 $ 39,852

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, 2015 2014 Raw materials $ 2,450 $ 2,603 Work in progress 3,636 4,056 Finished goods 12,599 12,053 Inventories $ 18,685 $ 18,712

Long-term Inventories (Tables)

Long-term Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Long Term Inventories Disclosure [Abstract]
Schedule of Inventory, Noncurrent [Table Text Block]	December 31, December 31, 2015 2014 Work in progress $ - $ - Finished goods - 2,648 Long-term Inventories $ - $ 2,648

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2015 2014 Cost Construction in progress $ 13,256 $ 8,206 Plant and buildings 30,852 32,211 Machinery and equipment 39,700 40,596 Motor vehicles 1,570 1,747 Equipment and furniture 2,566 2,542 Leasehold improvements 12,911 13,232 Total cost $ 100,855 $ 98,534 Less: Accumulated depreciation Construction in progress $ - $ - Plant and buildings 8,059 6,957 Machinery and equipment 20,458 17,876 Motor vehicles 1,408 1,567 Equipment and furniture 1,830 1,707 Leasehold improvements 5,160 4,194 Total accumulated depreciation $ 36,915 $ 32,301 Property, plant and equipment, net $ 63,940 $ 66,233

Prepaid Land Lease Payments (Ta

Prepaid Land Lease Payments (Tables)	12 Months Ended
	Dec. 31, 2015
Land use rights
Finite-Lived Intangible Assets [Line Items]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, December 31, 2015 2014 Prepaid land lease payments $ 11,147 $ 11,638 Less: accumulated amortization 1,573 1,377 Net carrying value $ 9,574 $ 10,261

Licenses (Tables)

Licenses (Tables)	12 Months Ended
	Dec. 31, 2015
Licenses
Finite-Lived Intangible Assets [Line Items]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	December 31, 2015 Accumulated Net book Cost amortization value Inactivated hepatitis A $ 3,261 $ 3,261 $ - Combined inactivated hepatitis A&B 470 470 - H5N1 licenses (note 24(c)) 1,419 1,419 - Total $ 5,150 $ 5,150 $ - December 31, 2014 Accumulated Net book Cost amortization value Inactivated hepatitis A $ 3,405 $ 3,405 $ - Combined inactivated hepatitis A&B 490 490 - H5N1 licenses (note 24(c)) 1,482 1,130 352 Total $ 5,377 $ 5,025 $ 352

Bank Loans and Other Debt (Tabl

Bank Loans and Other Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	December 31, 2015 2014 China Merchants Bank (a) $ 4,631 $ 4,835 Bank of Beijing (b) 2,933 8,059 Bank of China (c) 1,544 1,612 China Merchants Bank (d) 3,087 - Industrial and Commercial Bank of China (d) - 3,223 China Construction Bank (e) 7,719 - Bank loans due within one year 19,914 17,729 China Construction Bank (f) - 13,861 China Construction Bank (g) - 4,044 Bank of Beijing (h) - 11,741 Beijing Zhongguancun Development Group (i) 1,861 - Current portion of long-term bank loans and other debt 1,861 29,646 Bank of Beijing (h) 756 - Beijing Zhongguancun Development Group (i) - 1,803 Long-term bank loans and other debt 756 1,803 Total bank loans and other debt $ 22,531 $ 49,178 (a) In 2014, Sinovac Beijing entered into a bank loan with China Merchants Bank in the aggregate principal amount of $ 4,835 30 15 6.9 In 2015 Sinovac Beijing entered into a new bank loan with China Merchants Bank in the aggregate principal amount of $ 4,631 30 15 5.58 (b) In 2014, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $ 8,059 50 6 On September 18, 2015, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $ 7,719 50 4.35 1,467 9.5 1,466 9.5 (c) On December 17, 2012, Sinovac Dalian entered into a bank loan agreement with Bank of China with a credit line of $ 3,223 20 7.44 806 5 806 5 806 5 806 5 On March 17, 2015, Sinovac Dalian entered into a bank loan with Bank of China in the aggregate principal amount of $ 772 5 30 6.955 772 5 6.01 8,892 57.6 (d) In 2014, Sinovac Beijing entered into a bank loan with Industrial and Commercial Bank of China in the aggregate principal amount of $ 3,223 20 10 7.5 64 0.4 5,641 35 On November 5, 2015, Sinovac Beijing entered into a one-year term bank loan with China Merchants Bank in the aggregate principal amount of $ 3,087 20 5 4.57 62 0.4 5,403 35 (e) On June 4, 2015, Sinovac Beijing entered into a bank loan with China Construction Bank in the aggregate principal amount of $ 7,719 50 5.36 16,229 105.1 (f) The loan from China Construction Bank in the aggregate principal amount of $ 13,894 90 6.4 17,798 110 322 2 322 2 13,861 86 (g) The total amount of the loan facility from China Construction Bank was $ 8,059 50 4,996 31 6.15 10 10 458 3 494 3 3,874 25 (h) The loan from Bank of Beijing in the aggregate principal amount of $ 23,531 146 32,234 200 6.4 11,790 72.6 11,741 72.9 3,285 20.4 On May 20, 2015, Sinovac Beijing entered into a new bank loan with Bank of Beijing in the aggregate principal amount of $ 7,410 48 5.25 756 4.9 2,896 18.8 (i) The Loan from Beijing Zhongguancun Development Group in the aggregate principal amount of $ 1,934 12 0.36 967 6 967 6 10.62 358 6.9 376
Schedule of Maturities of Long Term Debt and Short Term Debt [Table Text Block]	Within 1 year $ 21,775 More than 1 year 756 Total $ 22,531

Related Party Transactions an45

Related Party Transactions and Balances (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transaction Due to Related Party [Table Text Block]	December 31, December 31, 2015 2014 Loan - current $ 2,470 $ 2,595
Schedule of Related Party Transactions [Table Text Block]	For the year ended December 31, 2015 2014 2013 Rent expenses payable to SinoBioway Biotech Group Co. Ltd. (“SinoBioway”). $ 852 $ 869 $ 847

Accounts Payable and Accrued 46

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2015 December 31, 2014 Trade payables $ 1,715 $ 3,033 Machinery and equipment payables 2,220 2,050 Accrued expenses 9,647 8,330 Value added tax payable 260 200 Other tax payable 183 171 Withholding tax payable 238 338 Bonus and benefit payables 5,231 5,626 Other payables 3,030 2,790 Total $ 22,524 $ 22,538

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The Company’s income before income tax from continuing operations consists of: For the year ended December 31, 2015 2014 2013 Non-PRC $ (2,802) $ (1,336) $ (65) PRC 5,833 3,982 9,476 Total $ 3,031 $ 2,646 $ 9,411
Schedule Of Income Before Income Tax From Discontinuing Operations, Domestic And Foreign [Table Text Block]	The Company’s (loss) before income tax from discontinued operations consists of: For the year ended December 31, 2015 2014 2013 Non-PRC $ - $ - $ - PRC (728) (1,524) (1,266) Total $ (728) $ (1,524) $ (1,266)
Summary Of Income Tax Expense Benefit By Operations [Table Text Block]	The benefit (provision) for income taxes for the years ended December 31, 2015, 2014 and 2013 was allocated between continuing operations and discontinued operations as follows: For the year ended December 31, 2015 2014 2013 Continuing operations $ (2,516) $ (1,458) $ 2,225 Discontinued operations - - - Total $ (2,516) $ (1,458) $ 2,225
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the year ended December 31, 2015 2014 2013 Current $ (3,034) $ (1,620) $ - Deferred 518 162 2,225 Total income tax benefit (expense) $ (2,516) $ (1,458) $ 2,225
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the year ended December 31, 2015 2014 2013 Income from continuing operations before income taxes $ 3,031 $ 2,646 $ 9,411 Income tax expense at the PRC statutory rate (758) (662) (2,352) International tax rate differential (701) (334) (16) Super deduction for research and development expenses 463 605 332 Non-deductible expenses (900) (524) (159) Other adjustments 139 (89) 297 Effect of preferential tax rate 1,350 901 1,573 Change in valuation allowance (1,618) (1,249) 2,550 Effect of PRC withholding tax (89) (106) - Effect of prior years’ income tax arising from tax inspection (402) - - Income tax benefit (expense) $ (2,516) $ (1,458) $ 2,225
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2015 2014 Accrued expenses $ 2,551 $ 2,410 Inventories 266 72 Prepaid expenses and deposits - (6) Deferred government grants 203 12 Less: valuation allowance (417) (222) Deferred tax assets, current portion $ 2,603 $ 2,266 Fixed assets 1,664 1,105 Deferred government grants 259 428 Tax losses carried forward 9,867 8,665 Less: valuation allowance (11,197) (9,683) Deferred tax assets, non-current portion $ 593 $ 515
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	For the year ended December 31, 2015 2014 2013 Balance at January 1 454 350 335 Additions for tax positions of the current year 159 160 15 Additions for tax positions of the prior years 281 - - Settlement with the taxing authority (103) - - Lapse of statute of limitations (35) (56) - Balance at December 31 $ 756 $ 454 $ 350

Deferred Government Grants (Tab

Deferred Government Grants (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Government Grant [Abstract]
Schedule Of Deferred Government Grants [Table Text Block]	Summarized below are deferred government grants as of December 31, 2015 and 2014: December 31, December 31, 2015 2014 Construction of a pandemic influenza vaccine plant and buildings (a) $ 278 $ 290 Purchasing equipment for H1N1 vaccine production (b) 137 143 Purchasing equipment for H5N1 vaccine production (c) 15 16 EV71 vaccine production facility (d) 259 - Research and development for EV71 (e) 77 - Loan from Zhongguancun Development Group (f) 358 - Others (g) 78 81 Current deferred government grants 1,202 530 Construction of a pandemic influenza vaccine plant and buildings (a) 848 1,176 Purchasing equipment for H1N1 vaccine production (b) 330 488 Purchasing equipment for H5N1 vaccine production (c) 46 64 EV71 vaccine production facility (d) 2,828 3,223 Research and development for EV71 (e) - 1,524 Loan from Zhongguancun Development Group (f) - 376 Others (g) 678 643 Non-current deferred government grants 4,730 7,494 Total deferred government grants $ 5,932 $ 8,024 (a) Deferred government grants included $ 1,126 7.3 20 1,466 9.1 278 1.8 848 5.5 287 290 237 (b) Deferred government grants also included $ 467 3.0 999 6.2 137 (RMB 0.8 330 2.2 141 143 119 (c) Deferred government grants also included $ 61 0.4 15 0.1 46 0.3 16 16 16 (d) The Company received a government grant in the amount of $ 3,087 20 259 1.7 2,828 18.3 (e) Deferred government grants also included $ 77 0.5 1,598 10 (f) The Company received a loan of $ 1,934 12 0.36 6.9 358 376 (g) Deferred government grants also included $ 756 4.9 678 4.4 642 4 78 0.5 81 0.5

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Minimum future rental payments under operating leases to related parties for the years ending December 31 are as follows: 2016 $ 852 2017 852 2018 852 2019 852 2020 852 Thereafter 8,601 Total minimum future payments $ 12,861

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2015 2014 2013 Expected volatility 51.42 % - - Risk-free interest rate 1.5 % - - Expected life (years) 5.5 - - Dividend yield 0 % - - Estimated forfeiture rate 7 % - -
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Aggregate Intrinsic Number Exercise Price Value of Options ($/option) ($) Outstanding as at January 1, 2015 637,200 $ 2.09 $ 1,997,644 Granted 1,341,000 4.98 - Exercised (367,900) 2.13 - Forfeited / Expired (129,900) 1.71 - Outstanding as at December 31, 2015 1,480,400 $ 4.73 $ 1,459,330 Vested and expected to vest at December 31, 2015 1,386,530 $ 4.72 $ 1,389,866 Exercisable as at December 31, 2015 139,400 $ 2.37 $ 466,990
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the Company’s non-vested restricted share activity for the 2012 plan is presented below: Number Weighted Average Non-vested as at January 1, 2015 — $ — Granted 729,000 4.98 Vested — — Forfeited / Expired — — Non-vested as at December 31, 2015 729,000 $ 4.98
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Number Number of Remaining Average Average of Remaining Exercise Options Contractual Exercise Options Contractual Average Exercise Prices Outstanding Life (years) Price Exercisable Life (years) Price ($/option) ($/option) ($/option) $ 2.37 139,400 1.99 $ 2.37 139,400 1.99 $ 2.37 $ 4.98 1,341,000 7.33 $ 4.98 - - - 1,480,400 6.83 139,400 1.99 $ 2.37

Earnings (loss) per Share (Tabl

Earnings (loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted income (loss) attributable to shareholders of Sinovac per share:: For the year ended December 31 2015 2014 2013 Numerator Income (loss) from continuing operations 515 1,188 11,636 Less: Income (loss) attributable to non-controlling interests 861 515 2,928 Income (loss) attributable to shareholders of Sinovac from continuing operations (346) 673 8,708 Income (loss) attributable to shareholders of Sinovac from discontinued operations (728) (1,524) (1,266) Net income (loss) attributable to shareholders of Sinovac (1,074) (851) 7,442 Denominator Basic weighted average number of common shares outstanding 56,313,927 55,681,076 55,301,276 Dilutive effect of stock options - 433,126 501,062 Diluted weighted average number of common shares outstanding 56,313,927 56,114,202 55,802,338 Basic net income (loss) per share Continuing operations (0.01) 0.01 0.15 Discontinued operations (0.01) (0.03) (0.02) Basic net income (loss) per share (0.02) (0.02) 0.13 Diluted net income (loss) per share Continuing operations (0.01) 0.01 0.15 Discontinued operations (0.01) (0.03) (0.02) Diluted net income (loss) per share (0.02) (0.02) 0.13

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule Of Total Assets By Geographic Area [Table Text Block]	December 31, 2015 December 31, 2014 Assets Mainland China $ 173,629 $ 207,645 Hong Kong 29,355 30,885 Total $ 202,984 $ 238,530
Revenue from External Customers by Products and Services [Table Text Block]	For the year ended December 31, 2015 2014 2013 Sales Inactivated hepatitis vaccines $ 49,416 $ 48,450 $ 47,202 Influenza vaccines 12,674 12,131 12,156 H5N1 3,852 201 10,736 Mumps 1,472 2,150 1,680 Total $ 67,414 $ 62,932 $ 71,774
Schedule Of Entity Wide Information Revenue From External Customers By Geographic Area [Table Text Block]	For the year ended December 31, 2015 2014 2013 Sales Mainland China $ 66,779 $ 61,955 $ 70,647 Foreign countries 635 977 1,127 Total $ 67,414 $ 62,932 $ 71,774

Condensed Financial Informati53

Condensed Financial Information of the Parent Company (Tables)	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Balance Sheet [Table Text Block]	December 31, December 31, 2015 2014 ASSETS Current assets Cash and cash equivalents $ 331 $ 997 Prepaid expenses and other receivables 70 9 Amount due from subsidiaries 66,032 69,824 Dividend receivables 21,280 21,280 Total current assets 87,713 92,110 Investment in subsidiaries 41,711 38,616 Total assets $ 129,424 $ 130,726 LIABILITIES AND EQUITY Current liabilities Accrued expenses and other payables $ 666 $ 584 Amount due to subsidiaries 5,478 3,578 Total current liabilities 6,144 4,162 Total liabilities $ 6,144 $ 4,162 EQUITY Preferred stock - - Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil Common stock 57 56 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 56,906,561 (2014 – 55,809,661) Additional paid-in capital 109,944 108,243 Accumulated other comprehensive income 8,110 12,022 Retained earnings 5,169 6,243 Total stockholders' equity 123,280 126,564 Total liabilities and equity $ 129,424 $ 130,726
Condensed Statement of Comprehensive Income [Table Text Block]	For the year ended December 31 2015 2014 2013 Selling, general and administrative expenses 2,563 2,466 2,710 Total operating expenses 2,563 2,466 2,710 Loss from operations (2,563) (2,466) (2,710) Other expense (5,053) - - Interest income 413 759 755 Equity earnings of subsidiaries, net of tax 6,129 856 9,397 Net income (loss) (1,074) (851) 7,442 Other comprehensive income (loss), net of tax of nil - - - Foreign currency translation adjustments (3,912) (2,119) 2,370 Total comprehensive income (loss) $ (4,986) $ (2,970) $ 9,812
Condensed Cash Flow Statement [Table Text Block]	For the year ended December 31 2015 2014 2013 Cash flows provided by (used in) operating activities Net income (loss) $ (1,074) $ (851) $ 7,442 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: -stock-based compensation 952 287 281 -equity in (earnings) of subsidiaries (6,129) (856) (9,397) Changes in: - Amount due from subsidiaries 3,792 (1,304) 2,505 - Prepaid expenses and other receivables (61) 114 59 - Dividend receivables - - 1,043 - Amount due to subsidiaries 1,900 1,815 1,130 - Accrued expenses and other payables 82 (336) (776) Net cash provided by (used in) operating activities (538) (1,131) 2,287 Cash flows provided by financing activities - Proceeds from issuance of common stock, net of share issuance costs 732 512 848 - Proceeds from shares subscribed 18 51 18 Net cash provided by financing activities 750 563 866 Cash flows provided by (used in) investing activities -Investment in subsidiaries (878) 165 (4,042) Net cash provided (used in) investing activities (878) 165 (4,042) Decrease in cash and cash equivalents (666) (403) (889) Cash and cash equivalents, beginning of year 997 1,400 2,289 Cash and cash equivalents, end of year $ 331 $ 997 $ 1,400

Basis of Presentation (Details)

Basis of Presentation (Details)	Dec. 31, 2015	Dec. 31, 2014
Sinovac Hong Kong
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	100.00%
Sinovac Beijing
Noncontrolling Interest, Ownership Percentage by Parent	73.09%	73.09%
Tangshan Yian
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	100.00%
Sinovac R&D
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	100.00%
Sinovac Dalian
Noncontrolling Interest, Ownership Percentage by Parent	55.00%	55.00%
Sinovac Bitomed Co., Ltd.
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	0.00%

Significant Accounting Polici55

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2015
Plant And Building [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	24 years
Plant And Building [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	8 years
Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	4 years
Office Equipment And Furniture [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years
Office Equipment And Furniture [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years

Significant Accounting Polici56

Significant Accounting Policies (Details Textual) $ in Thousands, ¥ in Millions	Aug. 15, 2012	Aug. 15, 2011	Dec. 31, 2014USD ($)	Jun. 30, 2014	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)	Dec. 31, 2012USD ($)
Long-term Debt, Percentage Bearing Fixed Interest, Amount					$ 1,861
Due to Related Parties, Current			$ 2,595		2,470	$ 2,595
Foreign Currency Transaction Gain (Loss), before Tax					(886)	(619)	$ 650
Cash and Cash Equivalents, at Carrying Value, Total			$ 91,293		63,834	91,293	106,517			$ 91,219
Gains Losses On Intra-entity Foreign Currency Transactions Long Term Investment Nature					560	294	235
Defined Contribution Plan, Cost Recognized					3,577	3,338	3,083
Advertising Expense					851	268	474
Shipping, Handling and Transportation Costs					1,389	1,235	1,215
Value Added Tax Rate			3.00%	6.00%
Asset Impairment Charges, Total					0	0	$ 57
Restricted Cash and Cash Equivalents, Current			$ 0		$ 1,626	0
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage					14.00%
Use Rights [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life					28 years
Use Rights [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life					49 years
Licensing Agreements [Member]
Finite-Lived Intangible Asset, Useful Life					9 years 1 month 28 days
Seasonal Influenza Vaccine [Member]
Revenue Recognition, Sales Returns, Reserve for Sales Returns					$ 1,462	1,320
Inactivated Hepatitis A Vaccine And Combined Inactivated Hepatitis A And B Vaccine [Member]
Revenue Recognition, Sales Returns, Reserve for Sales Returns					$ 5,900	$ 3,553
Percentage Of Sales Return Provision Of Private Pay Market Sales					13.60%	8.60%
H5 N1 Licenses [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
H5 N1 Licenses [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Asset, Useful Life		20 years
Denominated in RMB [Member]
Cash and Cash Equivalents, at Carrying Value, Total			$ 71,968		$ 46,923	$ 71,968		¥ 304	¥ 447

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales	$ 112	$ 169	$ 750
Cost of sales	406	1,017	768
Gross loss	(294)	(848)	(18)
Selling, general and administrative expenses	459	621	927
Research and development expenses	22	100	256
Total operating expenses	481	721	1,183
Operating (loss)	(775)	(1,569)	(1,201)
Other income (expense)	47	45	(65)
(Loss) before income taxes	(728)	(1,524)	(1,266)
Income tax benefit (expense)	0	0	0
(Loss) from discontinued operations, net of income tax	$ (728)	$ (1,524)	$ (1,266)

Discontinued Operations (Deta58

Discontinued Operations (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents	$ 143	$ 225
Prepaid land lease payments	128	144
Property, plant and equipment	1,450	2,184
Other assets held for sale	76	162
Total assets held for sale	1,797	2,715
Accounts payable and accrued liabilities	217	699
Other liabilities held for sale	26	28
Total liabilities held for sale	$ 243	$ 727

Discontinued Operations (Deta59

Discontinued Operations (Details Textual) - 12 months ended Dec. 31, 2015 ¥ in Thousands, $ in Thousands	USD ($)	CNY (¥)	CNY (¥)
Proceeds from Divestiture of Businesses	$ 776	¥ 5,030
Tangshan Yian Biological Engineering Co Ltd [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 2,069		¥ 13,000
Disposal Group, Including Discontinued Operation, Percentage of Ownership Sold	100.00%	100.00%

Restricted Cash (Details)

Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash	$ 1,626	$ 0

Restricted Cash (Details Textua

Restricted Cash (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents, Current	$ 1,626	$ 0

Accounts Receivable - net (Deta

Accounts Receivable - net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable, Net, Current, Total	$ 39,021	$ 40,719
Trade Accounts Receivable [Member]
Accounts Receivable, Gross, Current	40,733	42,423
Allowance for doubtful accounts	(2,415)	(2,571)
Accounts Receivable, Net, Current, Total	38,318	39,852
Other Receivables [Member]
Accounts Receivable, Net, Current, Total	$ 703	$ 867

Accounts Receivable - net (De63

Accounts Receivable - net (Details1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable, Net, Current, Total	$ 39,021	$ 40,719
Trade Accounts Receivable Aging Within One Year [Member]
Accounts Receivable, Net, Current, Total	34,495	35,130
Trade Accounts Receivable Aging Greater Than One Year [Member]
Accounts Receivable, Net, Current, Total	3,823	4,722
Trade Accounts Receivable [Member]
Accounts Receivable, Net, Current, Total	$ 38,318	$ 39,852

Accounts Receivable - net (De64

Accounts Receivable - net (Details Textual) $ / shares in Units, $ in Thousands, ¥ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)$ / shares	Dec. 31, 2013USD ($)$ / shares	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)
Accounts Receivable Pledged As Collateral For Bank Loan	$ 5,403	$ 5,641		¥ 35	¥ 35
Operating Income (Loss), Total | $	3,723	2,057	$ 9,946
Net Income (Loss) Available to Common Stockholders, Basic, Total | $	$ (1,074)	$ (851)	$ 7,442
Earnings Per Share, Basic, Total | $ / shares	$ (0.02)	$ (0.02)	$ 0.13
Earnings Per Share, Diluted, Total | $ / shares	$ (0.02)	$ (0.02)	$ 0.13
Accounts Receivables Aged More Than Four Years [Member]
Percentage Of Allowance For Accounts Receivable	100.00%	100.00%		100.00%	100.00%
Accounts Receivables Aged Between Three Year And Four Years [Member]
Percentage Of Allowance For Accounts Receivable	71.30%	100.00%		71.30%	100.00%
Accounts Receivables Aged Between Two Year And Three Years [Member]
Percentage Of Allowance For Accounts Receivable	38.60%	56.30%		38.60%	56.30%
Accounts Receivables Aged Between One Year And Two Years [Member]
Percentage Of Allowance For Accounts Receivable	13.60%	18.50%		13.60%	18.50%
Accounts Receivables Aged Less Than One Years [Member]
Percentage Of Allowance For Accounts Receivable	1.40%	1.80%		1.40%	1.80%
Accounts Receivables Aged More Than Three Years [Member] | Scenario, Adjustment [Member] | Uncollectible Receivables [Member]
Operating Income (Loss), Total | $	$ 375
Net Income (Loss) Available to Common Stockholders, Basic, Total | $	$ 274
Earnings Per Share, Basic, Total | $ / shares	$ 0
Earnings Per Share, Diluted, Total | $ / shares	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Raw materials	$ 2,450	$ 2,603
Work in progress	3,636	4,056
Finished goods	12,599	12,053
Inventories	$ 18,685	$ 18,712

Inventories (Details Textual)

Inventories (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fixed Production Overhead To Cost Of Sales	$ 2,154	$ 1,764	$ 1,790
Inventory Write-down	$ 1,820	$ 1,026	$ 1,052

Long-term Inventories (Details)

Long-term Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Work in progress	$ 0	$ 0
Finished goods	0	2,648
Long-term Inventories	$ 0	$ 2,648

Property, Plant and Equipment68

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Cost	$ 100,855	$ 98,534
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	36,915	32,301
Property, plant and equipment net	63,940	66,233
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Cost	13,256	8,206
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	0	0
Plant And Building [Member]
Property, Plant and Equipment [Line Items]
Cost	30,852	32,211
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	8,059	6,957
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	39,700	40,596
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	20,458	17,876
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Cost	1,570	1,747
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	1,408	1,567
Equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Cost	2,566	2,542
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	1,830	1,707
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	12,911	13,232
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 5,160	$ 4,194

Property, Plant and Equipment69

Property, Plant and Equipment (Details Textual) $ in Thousands, ¥ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013CNY (¥)
Property, Plant and Equipment [Line Items]
Depreciation, Total	$ 5,897	$ 7,458		$ 5,662
Gain (Loss) on Disposition of Assets, Total	26	74		31
Bank Of Beijing [Member] | Bank Of Beijing Term Loan Changping Facility [Member]
Property, Plant and Equipment [Line Items]
Debt Instrument, Collateral Amount		3,285				¥ 20.4
Sinovac Biotech Company Ltd [Member]
Property, Plant and Equipment [Line Items]
Impairment of Long-Lived Assets to be Disposed of	0	$ 0	¥ 0
Sinovac Biotech Company Ltd [Member] | China Construction Bank One [Member] | China Construction Bank Changping Facility [Member]
Property, Plant and Equipment [Line Items]
Debt Instrument, Collateral Amount	13,505			$ 17,798	¥ 87.5		¥ 110
Sinovac Biotech Company Ltd [Member] | Bank Of Beijing [Member] | Bank Of Beijing Term Loan Changping Facility [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Debt Instrument, Collateral Amount	2,568				16.6
Sinovac Dalian Vaccine Technology Company Ltd [Member] | Bank Of China [Member] | Bank Of China Term Loan [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Debt Instrument, Collateral Amount	$ 5,344				¥ 34.6

Prepaid Land Lease Payments (De

Prepaid Land Lease Payments (Details) - Land use rights - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Prepaid land lease payments	$ 11,147	$ 11,638
Less: accumulated amortization	1,573	1,377
Net carrying value	$ 9,574	$ 10,261

Prepaid Land Lease Payments (71

Prepaid Land Lease Payments (Details Textual) $ in Thousands, ¥ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)
Bank Of Beijing [Member] | Bank Of Beijing Term Loan Changping Facility [Member]
Finite-Lived Intangible Assets [Line Items]
Debt Instrument, Collateral Amount		$ 3,285			¥ 20.4
Land use rights
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 261	$ 267	$ 311
Land use rights | Sinovac Biotech Company Ltd [Member] | China Construction Bank Changping Facility [Member]
Finite-Lived Intangible Assets [Line Items]
Debt Instrument, Collateral Amount	2,724			¥ 17.6
Land use rights | Sinovac Biotech Company Ltd [Member] | Bank Of Beijing [Member] | Bank Of Beijing Term Loan Changping Facility [Member]
Finite-Lived Intangible Assets [Line Items]
Debt Instrument, Collateral Amount	327			2.1
Land use rights | Sinovac Dalian Vaccine Technology Company Ltd [Member] | Bank Of China [Member]
Finite-Lived Intangible Assets [Line Items]
Debt Instrument, Collateral Amount	$ 3,548			¥ 23

Licenses (Details)

Licenses (Details) - Licensing Agreements [Member] - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 5,150	$ 5,377
Finite-Lived Intangible Assets, Accumulated Amortization	5,150	5,025
Finite-Lived Intangible Assets, Net, Total	0	352
Inactivated Hepatitis A [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,261	3,405
Finite-Lived Intangible Assets, Accumulated Amortization	3,261	3,405
Finite-Lived Intangible Assets, Net, Total	0	0
Combined Inactivated Hepatitis A And B [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	470	490
Finite-Lived Intangible Assets, Accumulated Amortization	470	490
Finite-Lived Intangible Assets, Net, Total	0	0
H5 N1 Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,419	1,482
Finite-Lived Intangible Assets, Accumulated Amortization	1,419	1,130
Finite-Lived Intangible Assets, Net, Total	$ 0	$ 352

Licenses (Details Textual)

Licenses (Details Textual) - USD ($) $ in Thousands	Aug. 15, 2012	Aug. 15, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
H5 N1 Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life			9 years 1 month 28 days
Amortization of Intangible Assets			$ 352	$ 371	$ 435
Licensing Agreements [Member] | H5 N1 Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		20 years

Bank Loans and Other Debt (Deta

Bank Loans and Other Debt (Details) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Bank loans		$ 19,914	$ 17,729
Current portion of long-term bank loans and other debt		1,861	29,646
Long-term bank loans and other debt		756	1,803
Total bank loans and other debt		22,531	49,178
China Merchants Bank One [Member]
Line of Credit Facility [Line Items]
Bank loans	[1]	4,631	4,835
Bank Of Beijing [Member]
Line of Credit Facility [Line Items]
Bank loans	[2]	2,933	8,059
Current portion of long-term bank loans and other debt	[3]	0	11,741
Long-term bank loans and other debt	[3]	756	0
Bank Of China [Member]
Line of Credit Facility [Line Items]
Bank loans	[4]	1,544	1,612
Industrial And Commercial Bank Of China [Member]
Line of Credit Facility [Line Items]
Bank loans	[5]	0	3,223
China Construction Bank One [Member]
Line of Credit Facility [Line Items]
Bank loans	[6]	7,719	0
Current portion of long-term bank loans and other debt	[7]	0	13,861
Beijing Zhongguancun Development Group [Member]
Line of Credit Facility [Line Items]
Current portion of long-term bank loans and other debt	[8]	1,861	0
Long-term bank loans and other debt	[8]	0	1,803
China Merchants Bank Two [Member]
Line of Credit Facility [Line Items]
Bank loans	[5]	3,087	0
China Construction Bank Two [Member]
Line of Credit Facility [Line Items]
Current portion of long-term bank loans and other debt	[9]	$ 0	$ 4,044
[1]	In 2014, Sinovac Beijing entered into a bank loan with China Merchants Bank in the aggregate principal amount of $4,835 (RMB 30 million) to finance its working capital requirements, bearing interest at 15% above the prime rate of a one-year term loan published by the People’s Bank of China, at 6.9% per year. Interest was payable quarterly. The loan was drawn on March 3, 2014 and was repaid on March 2, 2015. Sinovac Beijing entered into a new bank loan with China Merchants Bank in the aggregate principal amount of $4,631 (RMB 30 million) to finance its working capital requirements on June 30, 2015, bearing interest at 15% above the prime rate of a one-year term loan published by the People’s Bank of China, at 5.58% per year. Interest is payable quarterly. The loan was drawn on June 30, 2015 and is repayable on June 28, 2016.
[2]	In 2014, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $8,059 (RMB 50 million) to finance its working capital requirements. The loan’s annual interest rate was 6% and was payable quarterly. The loan was repaid in full on August 28, 2015. On September 18, 2015, Sinovac Beijing entered into a bank loan with Bank of Beijing in the aggregate principal amount of $7,719 (RMB 50 million) to finance its working capital requirements. The loan bears interest at 4.35% and is payable quarterly. The first $1,467 (RMB 9.5 million) was drawn on October 28, 2015 and is payable on October 27, 2016. The second $1,466 (RMB 9.5 million) was drawn on November 30, 2015 and is repayable on November 29, 2016.
[3]	The loan from Bank of Beijing in the aggregate principal amount of $23,531 (RMB 146 million) with a term from May 2011 to November 2015 was for construction of the Changping facility and had a maximum credit facility amount of $32,234 (RMB 200 million). The interest was charged at the bank’s prime lending rate and adjusted every 12 months, at 6.4% per year, and was payable quarterly. The loan was repayable in four installments on May 13, 2014, November 13, 2014, May 13, 2015 and November 13, 2015. $11,790 (RMB 72.6 million) was repaid in 2014 and $11,741 (RMB 72.9 million) was repaid in 2015. Prepaid land lease payments and buildings of Sinovac Beijing with a net book value of $3,285 (RMB 20.4 million) were pledged as collateral as of December 31, 2014. On May 20, 2015, Sinovac Beijing entered into a new bank loan with Bank of Beijing in the aggregate principal amount of $7,410 (RMB 48 million) with a term from July 2015 to July 2020 for construction of the pneumococcal polysaccharide vaccine facilities. The loan bears interest at the bank’s prime lending rate, at 5.25% per year. Interest is payable quarterly. The loan is repayable in four equal installments in January 2019, July 2019, January 2020 and July 2020. $756 (RMB 4.9 million) was drawn in July 2015. Prepaid land lease payments and buildings of Sinovac Beijing with a net book value of $2,896 (RMB 18.8 million) were pledged as collateral as of December 31, 2015.
[4]	On December 17, 2012, Sinovac Dalian entered into a bank loan agreement with Bank of China with a credit line of $3,223 (RMB 20 million). The loan’s annual interest rate was 7.44%. The first $806 (RMB 5 million) was drawn down on March 13, 2013 and repaid on March 12, 2014. The second $806 (RMB 5 million) was drawn down on September 24, 2013 and repaid on September 23, 2014. The third $806 (RMB 5 million) was drawn down on March 31, 2014 and was repaid on March 26, 2015. The fourth $806 (RMB 5 million) was drawn down on September 23, 2014 and was repaid in full on September 22, 2015. On March 17, 2015, Sinovac Dalian entered into a bank loan with Bank of China in the aggregate principal amount of $772 (RMB 5 million) to finance its working capital requirements. The loan bears interest at 30% above the prime rate of a one-year term loan published by the People’s Bank of China, at 6.955%, the interest is paid monthly, and the loan will be repaid on March 16, 2016. On October 26, 2015, Sinovac Dalian entered into a bank loan with Bank of China in the aggregate principal amount of $772 (RMB 5 million) to finance its working capital requirements. The loan bears interest at 166 base points above the prime rate of a one-year term loan published by the People’s Bank of China, at 6.01%, interest is paid monthly and the loan is repayable on October 28, 2016. Prepaid land lease payments and buildings of Sinovac Dalian with a net book value of $8,892 (RMB 57.6 million) were pledged as collateral.
[5]	In 2014, Sinovac Beijing entered into a bank loan with Industrial and Commercial Bank of China in the aggregate principal amount of$3,223 (RMB 20 million) to finance its working capital requirements, bearing interest at 10% above the prime rate of a one-year term loan published by the People’s Bank of China at 7.5% per year. Interest was payable monthly. The loan was drawn on June 19, 2014, and guaranteed by an unrelated third party, with a guarantee fee of $64 (RMB 0.4 million) over the term of the loan. Trade receivables of Sinovac Beijing with a carrying value of not lower than $5,641 (RMB 35 million) were pledged as collateral. The loan was fully repaid on June 30, 2015.On November 5, 2015 Sinovac Beijing entered into a one-year term bank loan with China Merchants Bank in the aggregate principal amount of $3,087 (RMB 20 million) to finance its working capital requirements, bearing interest at 5% above the prime rate of a one-year term loan published by the People’s Bank of China, at 4.57% per year. Interest is payable quarterly. The loan is guaranteed by an unrelated third party, with a guarantee fee of $62 (RMB 0.4 million) over the term of the loan. Trade receivables of Sinovac Beijing with a carrying value of not lower than $5,403 (RMB 35 million) were pledged as collateral.
[6]	On June 4, 2015,Sinovac Beijing entered into a bank loan with China Construction Bank in the aggregate principal amount of $7,719 (RMB50 million) to finance its working capital requirements, bearing interest at 5% above the prime rate of a one-year term loan published by the People’s Bank of China and the interest rate of current year is 5.36%. Interest is payable monthly. The loan was drawn by three installments on June 4, 2015, June 29, 2015, and August 7, 2015, and is repayable on June 3, 2016. Pursuant to the covenants set out in the agreement, the debt to total assets ratio must not be higher than 80%, the current ratio must not be lower than 0.8, contingent liabilities must not be higher than $24,830 (RMB 161 million) and contingent liabilities as a percentage of total shareholders’ equity must not be higher than 50%. The Company is in compliance with such covenants as of December 31, 2015.Prepaid land lease payment and buildings of the Changping facilities of Sinovac Beijing with a net book value of $16,229 (RMB 105.1 million) were pledged as collateral.
[7]	The loan from China Construction Bank in the aggregate principal amount of $13,894 (RMB 90 million) was exclusively for the purchase of the Changping facility, bearing interest at the bank’s prime lending rate and adjusted every 12 months, at 6.4% per year. Interest was payable monthly. Prepaid land lease payment and buildings of the Changping facilities of Sinovac Beijing with a net book value of $17,798 (RMB 110 million) were pledged as collateral. $322 (RMB 2 million) was repaid in 2013, $322 (RMB 2 million) was repaid in 2014, and the remaining $13,861 (RMB 86 million) was fully repaid in 2015.
[8]	The Loan from Beijing Zhongguancun Development Group in the aggregate principal amount of $1,934 (RMB 12 million) bearing interest currently at 0.36% per year is for the purpose of funding EV71 vaccine research project of Sinovac Beijing. The total loan is $1,934 (RMB 12 million) of which $967 (RMB 6 million) was received in 2012 and the second $967 (RMB 6 million) was received in 2013. The loan is unsecured and repayable on February 24, 2016. Beijing Zhongguancun Development Group is entitled to 10.62% ownership of the profits, if any, generated from the intellectual property developed during the loan period. No profit-sharing payments are required to be made as no profits have been generated to date. The Company can repay the loan at any time during the loan period. The fair value differential of $358 (between the face value and the fair value using the effective interest rate method at the Company's borrowing rate of 6.9%) is recorded as current deferred government grant as of December 31, 2015 (2014- $376) (see note 16). The loan was repaid in full on February 22, 2016.
[9]	The total amount of the loan facility from China Construction Bank was $8,059 (RMB 50 million) for a three-year period from December 13, 2012 to December 12, 2015. The amount drawn was $4,996 (RMB 31 million) as at December 31, 2014. Interest was set at the bank’s prime lending rate at 6.15% per year. The loan was to be used exclusively for the operation and production costs of Sinovac Beijing. Interest was payable monthly. The loan was unsecured. 10% of the principal amount was repayable in 2013 and 10% of the principal amount was repayable in 2014 with the remaining principal repayable in 2015. $458 (RMB 3 million) was repaid in 2013 and $494 (RMB 3 million) was repaid in 2014, and the remaining $3,874 (RMB 25 million) was fully repaid in 2015.

Bank Loans and Other Debt (De75

Bank Loans and Other Debt (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Aggregate annual principal payments of loans payable
Within 1 year	$ 21,775	$ 47,375
More than 1 year	756
Total	$ 22,531	$ 49,178

Bank Loans and Other Debt (De76

Bank Loans and Other Debt (Details Textual) $ in Thousands, ¥ in Millions		Jun. 04, 2015USD ($)	Nov. 05, 2014USD ($)	Nov. 05, 2014CNY (¥)	Mar. 13, 2013USD ($)	Mar. 13, 2013CNY (¥)	Nov. 30, 2015USD ($)	Nov. 30, 2015CNY (¥)	Oct. 28, 2015USD ($)	Oct. 28, 2015CNY (¥)	Oct. 26, 2015USD ($)	Oct. 26, 2015CNY (¥)	Sep. 30, 2015	May. 20, 2015USD ($)	Mar. 17, 2015USD ($)	Mar. 17, 2015CNY (¥)	Sep. 23, 2014USD ($)	Sep. 23, 2014CNY (¥)	Mar. 31, 2014USD ($)	Mar. 31, 2014CNY (¥)	Sep. 24, 2013USD ($)	Sep. 24, 2013CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2013CNY (¥)	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Dec. 31, 2015CNY (¥)	Sep. 18, 2015USD ($)	Sep. 18, 2015CNY (¥)	Jul. 31, 2015USD ($)	Jul. 31, 2015CNY (¥)	Jun. 30, 2015	Jun. 04, 2015CNY (¥)	May. 20, 2015CNY (¥)	Dec. 31, 2014CNY (¥)	Nov. 05, 2014CNY (¥)	Dec. 31, 2013CNY (¥)	Dec. 17, 2012USD ($)	Dec. 17, 2012CNY (¥)
Line of Credit Facility [Line Items]
Proceeds from Issuance of Debt																							$ 21,312		$ 17,837		$ 16,800
Repayments of Debt																							46,786		15,962		$ 4,089
Loans Payable, Current, Total																							1,861		29,646
Deferred Government Grants Current And Noncurrent																							$ 5,932		$ 8,024
Short-term Debt, Weighted Average Interest Rate																							6.00%		6.80%		7.00%				6.00%								6.80%		7.00%
Interest Costs Incurred, Total																							$ 2,059		$ 3,374		$ 2,942
Interest Costs Capitalized																									0		$ 116
China Merchants Bank One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.57%																																					4.57%
China Merchants Bank One [Member] | Sinovac Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount			$ 3,087
Debt Instrument, Basis Spread on Variable Rate			5.00%	5.00%
Debt Instrument, Collateral Amount			$ 5,403																																					¥ 35
Debt Instrument Guarantee Fee			$ 62	¥ 0.4
Bank Of Beijing [Member]
Line of Credit Facility [Line Items]
Repayments of Debt																							11,741	¥ 72.9
Loans Payable, Current, Total	[1]																						0		11,741
Bank Of Beijing [Member] | Sinovac Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate													4.35%
Proceeds from Issuance of Debt							$ 1,466	¥ 9.5	$ 1,467	¥ 9.5
Bank Of China [Member] | Sinovac Dalian Vaccine Technology Company Ltd [Member] | Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																																										7.44%	7.44%
Proceeds from Issuance of Debt					$ 806	¥ 5											$ 806	¥ 5	$ 806	¥ 5	$ 806	¥ 5
Line of Credit Facility, Maximum Borrowing Capacity																																										$ 3,223	¥ 20
Bank Of China [Member] | Sinovac Dalian [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Effective Percentage											6.01%	6.01%			6.955%	6.955%
Proceeds from Issuance of Debt											$ 772	¥ 5
China Construction Bank One [Member]
Line of Credit Facility [Line Items]
Loans Payable, Current, Total	[2]																						0		13,861
Beijing Zhongguancun Development Group [Member]
Line of Credit Facility [Line Items]
Loans Payable, Current, Total	[3]																						1,861		0
China Construction Bank Two [Member]
Line of Credit Facility [Line Items]
Repayments of Debt																							3,874	¥ 25
Loans Payable, Current, Total	[4]																						0		4,044
Bank Term Loan Drawn In March 2014 [Member] | China Merchants Bank One [Member] | Sinovac Biotech Company Ltd [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																							$ 4,631		$ 4,835						¥ 30								¥ 30
Debt Instrument, Interest Rate, Effective Percentage																									6.90%											5.58%			6.90%
Bank Term Loan Drawn In March 2014 [Member] | China Merchants Bank One [Member] | Sinovac Biotech Company Ltd [Member] | Prime Rate [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate																							15.00%	15.00%	15.00%	15.00%
Bank Term Loan Drawn In August 2014 [Member] | Bank Of Beijing [Member] | Sinovac Biotech Company Ltd [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																									$ 8,059														¥ 50
Debt Instrument, Interest Rate, Stated Percentage																									6.00%														6.00%
Bank Term Loan Drawn In June 2014 [Member] | Industrial And Commercial Bank Of China [Member] | Sinovac Biotech Company Ltd [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																									$ 3,223														¥ 20
Debt Instrument, Interest Rate, Effective Percentage																									7.50%														7.50%
Debt Instrument, Collateral Amount																									$ 5,641														¥ 35
Debt Instrument Guarantee Fee																									$ 64	¥ 0.4
Bank Term Loan Drawn In June 2014 [Member] | Industrial And Commercial Bank Of China [Member] | Sinovac Biotech Company Ltd [Member] | Prime Rate [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate																									10.00%	10.00%
China Construction Bank Changping Facility [Member] | Bank Of Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument Adjustment of Variable Rate Basis Term																									12 years	12 years
China Construction Bank Changping Facility [Member] | China Construction Bank One [Member] | Sinovac Biotech Company Ltd [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Effective Percentage																									6.40%		6.40%												6.40%		6.40%
Debt Instrument, Collateral Amount																							$ 13,505				$ 17,798				87.5										¥ 110
Loans Payable, Total																									$ 13,894														¥ 90
Debt Instrument Adjustment of Variable Rate Basis Term																									12 years	12 years	12 years	12 years
Repayments of Debt																									$ 322	¥ 2	$ 322	¥ 2
Loans Payable, Current, Total																							13,861								86
China Construction Bank Line Of Credit Sinovac Beijing [Member] | China Construction Bank One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																							8,059								50
Debt Instrument, Interest Rate, Stated Percentage																									6.15%		6.15%												6.15%		6.15%
Loans Payable, Total																									$ 4,996														¥ 31
Repayments of Debt																									$ 494	3	$ 458	3
Debt Instrument Percentage of Debt Repayable In Current Period																									10.00%		10.00%												10.00%		10.00%
Bank Of Beijing Term Loan Changping Facility [Member] | Bank Of Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Effective Percentage																									6.40%														6.40%
Line of Credit Facility, Maximum Borrowing Capacity																									$ 32,234														¥ 200
Debt Instrument, Collateral Amount																									3,285														20.4
Loans Payable, Total																									23,531														¥ 146
Repayments of Debt																									$ 11,790	¥ 72.6
Term Loan For Funding Vaccine Research Project [Member] | Beijing Zhongguancun Development Group [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																							$ 1,934								¥ 12
Debt Instrument, Interest Rate, Stated Percentage																							0.36%								0.36%
Proceeds from Issuance of Debt																											$ 967	¥ 6	$ 967	¥ 6
Percentage of Ownership Profit To Which Lender Of Debt Is Entitled																									10.62%														10.62%
Deferred Government Grants Current And Noncurrent																							$ 358		$ 376
Fair Value Inputs, Discount Rate																							6.90%	6.90%	6.90%	6.90%
Bank Term Loan Drawn On October 2015 [Member] | Bank Of Beijing [Member] | Sinovac Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount																																$ 7,719	¥ 50
Bank Term Loan Drawn On October 2015 [Member] | Bank Of China [Member] | Sinovac Dalian [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate															30.00%	30.00%
Proceeds from Issuance of Debt															$ 772	¥ 5
Debt Instrument, Collateral Amount | ¥																															¥ 57.6
Bank Term Loan Drawn On June 2015 [Member] | Bank Of China [Member] | Sinovac Dalian [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Collateral Amount																							$ 8,892
Bank Term Loan Drawn On June 2015 [Member] | China Construction Bank One [Member] | Sinovac Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount		$ 7,719																																			¥ 50
Debt Instrument, Basis Spread on Variable Rate		5.36%
Debt Instrument, Collateral Amount		$ 16,229																																			¥ 105.1
Debt Instrument, Covenant Description																							the debt to total assets ratio must not be higher than 80%, the current ratio must not be lower than 0.8, contingent liabilities must not be higher than $24,830 (RMB 161 million) and contingent liabilities as a percentage of total shareholders’ equity must not be higher than 50%	the debt to total assets ratio must not be higher than 80%, the current ratio must not be lower than 0.8, contingent liabilities must not be higher than $24,830 (RMB 161 million) and contingent liabilities as a percentage of total shareholders’ equity must not be higher than 50%
Bank Term Loan Drawn On July 2015 [Member] | Bank Of Beijing [Member] | Sinovac Beijing [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount														$ 7,410																								¥ 48
Debt Instrument, Basis Spread on Variable Rate														5.25%
Debt Instrument, Collateral Amount																							$ 2,896								¥ 18.8
Loans Payable, Current, Total																																		$ 756	¥ 4.9
Short Term And Long Term Bank Loan [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Effective Percentage																							6.00%		6.80%		6.60%				6.00%								6.80%		6.60%
[1]	The loan from Bank of Beijing in the aggregate principal amount of $23,531 (RMB 146 million) with a term from May 2011 to November 2015 was for construction of the Changping facility and had a maximum credit facility amount of $32,234 (RMB 200 million). The interest was charged at the bank’s prime lending rate and adjusted every 12 months, at 6.4% per year, and was payable quarterly. The loan was repayable in four installments on May 13, 2014, November 13, 2014, May 13, 2015 and November 13, 2015. $11,790 (RMB 72.6 million) was repaid in 2014 and $11,741 (RMB 72.9 million) was repaid in 2015. Prepaid land lease payments and buildings of Sinovac Beijing with a net book value of $3,285 (RMB 20.4 million) were pledged as collateral as of December 31, 2014. On May 20, 2015, Sinovac Beijing entered into a new bank loan with Bank of Beijing in the aggregate principal amount of $7,410 (RMB 48 million) with a term from July 2015 to July 2020 for construction of the pneumococcal polysaccharide vaccine facilities. The loan bears interest at the bank’s prime lending rate, at 5.25% per year. Interest is payable quarterly. The loan is repayable in four equal installments in January 2019, July 2019, January 2020 and July 2020. $756 (RMB 4.9 million) was drawn in July 2015. Prepaid land lease payments and buildings of Sinovac Beijing with a net book value of $2,896 (RMB 18.8 million) were pledged as collateral as of December 31, 2015.
[2]	The loan from China Construction Bank in the aggregate principal amount of $13,894 (RMB 90 million) was exclusively for the purchase of the Changping facility, bearing interest at the bank’s prime lending rate and adjusted every 12 months, at 6.4% per year. Interest was payable monthly. Prepaid land lease payment and buildings of the Changping facilities of Sinovac Beijing with a net book value of $17,798 (RMB 110 million) were pledged as collateral. $322 (RMB 2 million) was repaid in 2013, $322 (RMB 2 million) was repaid in 2014, and the remaining $13,861 (RMB 86 million) was fully repaid in 2015.
[3]	The Loan from Beijing Zhongguancun Development Group in the aggregate principal amount of $1,934 (RMB 12 million) bearing interest currently at 0.36% per year is for the purpose of funding EV71 vaccine research project of Sinovac Beijing. The total loan is $1,934 (RMB 12 million) of which $967 (RMB 6 million) was received in 2012 and the second $967 (RMB 6 million) was received in 2013. The loan is unsecured and repayable on February 24, 2016. Beijing Zhongguancun Development Group is entitled to 10.62% ownership of the profits, if any, generated from the intellectual property developed during the loan period. No profit-sharing payments are required to be made as no profits have been generated to date. The Company can repay the loan at any time during the loan period. The fair value differential of $358 (between the face value and the fair value using the effective interest rate method at the Company's borrowing rate of 6.9%) is recorded as current deferred government grant as of December 31, 2015 (2014- $376) (see note 16). The loan was repaid in full on February 22, 2016.
[4]	The total amount of the loan facility from China Construction Bank was $8,059 (RMB 50 million) for a three-year period from December 13, 2012 to December 12, 2015. The amount drawn was $4,996 (RMB 31 million) as at December 31, 2014. Interest was set at the bank’s prime lending rate at 6.15% per year. The loan was to be used exclusively for the operation and production costs of Sinovac Beijing. Interest was payable monthly. The loan was unsecured. 10% of the principal amount was repayable in 2013 and 10% of the principal amount was repayable in 2014 with the remaining principal repayable in 2015. $458 (RMB 3 million) was repaid in 2013 and $494 (RMB 3 million) was repaid in 2014, and the remaining $3,874 (RMB 25 million) was fully repaid in 2015.

Related Party Transactions an77

Related Party Transactions and Balances (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Loan - current	$ 2,470	$ 2,595

Related Party Transactions an78

Related Party Transactions and Balances (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sino Bioway
Rent expenses payable to SinoBioway Biotech Group Co. Ltd. ("SinoBioway").	$ 852	$ 869	$ 847

Related Party Transactions an79

Related Party Transactions and Balances (Details Textual) $ in Thousands, ¥ in Millions	Apr. 08, 2013	Aug. 12, 2010USD ($)	Aug. 12, 2010CNY (¥)	Aug. 12, 2004	Sep. 30, 2010USD ($)	Sep. 30, 2010CNY (¥)	Jun. 30, 2007USD ($)	Jun. 30, 2007CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2004USD ($)	Dec. 31, 2004CNY (¥)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)
Interest Expense, Related Party									$ 183	$ 221		$ 237
Repayment of Loan To Related Party									$ 199	649	¥ 4	237
Dalian Jin Gang Group [Member]
Debt Instrument, Interest Rate, Stated Percentage									7.20%						7.20%
Interest Expense, Related Party									$ 183	221		$ 237
Interest Payable Included in Loan From Related Party										16
Sino Bioway Biotech Group Holding Limited [Member]
Related Party Transaction, Prepaid Lease Payments									$ 377	$ 389					¥ 2.4	¥ 2.4
Related Party Transaction Operating Leases Number of Lease Agreements Amended		1	1
Related Party Transaction Number of Supplemental Agreements With Related Party	3
Related Party Transaction Number of Operating Lease Agreements for Which Expiration Date is Extended	4
Sino Bioway Biotech Group Holding Limited [Member] | Operating Lease Agreements Production Plant And Laboratory [Member]
Related Party Transaction, Operating Lease Annual Rent													$ 220	¥ 1.4
Related Party Transaction, Lease Term				20 years
Sino Bioway Biotech Group Holding Limited [Member] | Operating Lease Agreement Before Amendment Production Plant And Laboratory [Member]
Related Party Transaction, Operating Lease Annual Rent		$ 81	¥ 0.5
Sino Bioway Biotech Group Holding Limited [Member] | Operating Lease Agreement After Amendment Production Plant And Laboratory [Member]
Related Party Transaction, Operating Lease Annual Rent		$ 220	¥ 1.4
Sino Bioway Biotech Group Holding Limited [Member] | Operating Lease Agreement Expansion Of Production Plant [Member]
Related Party Transaction, Operating Lease Annual Rent							$ 325
Sino Bioway Biotech Group Holding Limited [Member] | Operating Lease Agreement Expansion Of Research And Development Business [Member]
Related Party Transaction, Operating Lease Annual Rent					$ 161	¥ 1		¥ 2
Related Party Transaction, Lease Term					5 years	5 years	20 years	20 years

Accounts Payable and Accrued 80

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Trade payables	$ 1,715	$ 3,033
Machinery and equipment payables	2,220	2,050
Accrued expenses	9,647	8,330
Value added tax payable	260	200
Other tax payable	183	171
Withholding tax payable	238	338
Bonus and benefit payables	5,231	5,626
Other payables	3,030	2,790
Total	$ 22,524	$ 22,538

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income (loss) before income tax from continuing operations
Non-PRC	$ (2,802)	$ (1,336)	$ (65)
PRC	5,833	3,982	9,476
Total	$ 3,031	$ 2,646	$ 9,411

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income (loss) before income tax from discontinued operations
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	$ (728)	$ (1,524)	$ (1,266)
Non-PRC [Member]
Income (loss) before income tax from discontinued operations
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	0	0	0
PRC [Member]
Income (loss) before income tax from discontinued operations
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	$ (728)	$ (1,524)	$ (1,266)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Expense (Benefit)	$ 2,516	$ 1,458	$ (2,225)
Continuing Operations [Member]
Income Tax Expense (Benefit)	(2,516)	(1,458)	2,225
Discontinued Operations [Member]
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income taxes attributed to the operations in China
Current	$ (3,034)	$ (1,620)	$ 0
Deferred	518	162	2,225
Total income tax benefit (expense)	$ (2,516)	$ (1,458)	$ 2,225

Income Taxes (Details 4)

Income Taxes (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of income taxes
Income from continuing operations before income taxes	$ 3,031	$ 2,646	$ 9,411
Income tax expense at the PRC statutory rate	(758)	(662)	(2,352)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount	(701)	(334)	(16)
Super deduction for research and development expenses	463	605	332
Non-deductible expenses	(900)	(524)	(159)
Other adjustments	139	(89)	297
Effect of preferential tax rate	1,350	901	1,573
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	(1,618)	(1,249)	2,550
Effect of PRC withholding tax	(89)	(106)	0
Effect of prior years' income tax arising from tax inspection	(402)	0	0
Income tax benefit (expense)	$ 2,516	$ 1,458	$ (2,225)

Income Taxes (Details 5)

Income Taxes (Details 5) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Tax effects of temporary differences giving rise to deferred tax assets
Accrued expenses	$ 2,551	$ 2,410
Inventories	266	72
Prepaid expenses and deposits	0	(6)
Deferred government grants	203	12
Less: valuation allowance	(417)	(222)
Deferred tax assets, current portion	2,603	2,266
Fixed assets	1,664	1,105
Deferred government grants	259	428
Tax losses carried forward	9,867	8,665
Less: valuation allowance	(11,197)	(9,683)
Deferred tax assets,non-current portion	$ 593	$ 515

Income Taxes (Details 6)

Income Taxes (Details 6) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unrecognized tax benefit
Balance at January 1	$ 454	$ 350	$ 335
Additions for tax positions of the current year	159	160	15
Additions for tax positions of the prior years	281	0	0
Settlement with the taxing authority	(103)	0	0
Lapse of statute of limitations	(35)	(56)	0
Balance at December 31	$ 756	$ 454	$ 350

Income Taxes (Details Textual)

Income Taxes (Details Textual) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2015CNY (¥)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		25.00%	25.00%	25.00%	25.00%	25.00%	25.00%	25.00%	25.00%
Components of Deferred Tax Assets [Abstract]
Deferred Tax Assets, Valuation Allowance		$ 11,614	$ 9,905
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Increase in Unrecognized Tax Benefits is Reasonably Possible		281
Unrecognized Tax Benefits		756	454	$ 350	$ 335
Income Tax Examination Expenses		397
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		607	454	350
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total		(728)	(1,524)	(1,266)
Discontinued Operations [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total		0	$ 0	$ 0
Minimum [Member]
Operating Loss Carryforward [Abstract]
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Domestic Subsidiaries		537
Maximum [Member]
Operating Loss Carryforward [Abstract]
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Domestic Subsidiaries		1,073
Sinovac Beijing [Member]
Operating Loss Carryforward [Abstract]
Undistributed Earnings of Domestic Subsidiaries		10,733
PRC Subsidiaries [Member]
Operating Loss Carryforward [Abstract]
Operating Loss Carryforwards		$ 39,466								¥ 238
Income Tax Statute Of Limitation For Transfer Pricing Related Matters		10 years
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Operating Loss Carryforwards Expiration Period		will expire from 2016 to 2020.
PRC Subsidiaries [Member] | Minimum [Member]
Operating Loss Carryforward [Abstract]
Income Tax Statute Of Limitation For Transfer Pricing Related Matters		3 years
PRC Subsidiaries [Member] | Maximum [Member]
Operating Loss Carryforward [Abstract]
Income Tax Statute Of Limitation For Transfer Pricing Related Matters		5 years
PRC [Member]
Withholding Income Tax [Abstract]
Lower Withholding Tax Rate On Dividends Distributed By Foreign Invested Enterprises		5.00%
Higher Withholding Tax Rate On Dividends Distributed By Foreign Invested Enterprises		10.00%
PRC [Member] | Sinovac Beijing [Member]
Income Taxes Preferential Income Tax Rate		15.00%	15.00%
Income Taxes Preferential Income Tax Rate Review Period			3 years
PRC [Member] | Sinovac Beijing [Member] | Future Tax Rate [Member]
Income Taxes Preferential Income Tax Rate	15.00%
PRC [Member] | PRC Subsidiaries [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		25.00%

Deferred Revenue (Details Textu

Deferred Revenue (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Current	$ 8,144	$ 4,996
Deferred Revenue, Noncurrent	0	7,191
Prc Government Stockpiling Purchase Of H5N1 Vaccines [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Current	6,549	3,546
Deferred Revenue, Noncurrent	0	7,191
Advances from customers [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue, Current	$ 1,595	$ 1,450

Deferred Government Grants (Det

Deferred Government Grants (Details) - USD ($) $ in Thousands		Dec. 31, 2015	Dec. 31, 2014
Current deferred government grants		$ 1,202	$ 530
Non-current deferred government grants		4,730	7,494
Total deferred government grants		5,932	8,024
Construction of a pandemic influenza vaccine plant and buildings [Member]
Current deferred government grants	[1]	278	290
Non-current deferred government grants	[1]	848	1,176
Purchasing equipment for H1N1 vaccine production [Member]
Current deferred government grants	[2]	137	143
Non-current deferred government grants	[2]	330	488
Purchasing equipment for H5N1 vaccine production [Member]
Current deferred government grants	[3]	15	16
Non-current deferred government grants	[3]	46	64
Research and development for EV71 [Member]
Current deferred government grants	[4]	259	0
Non-current deferred government grants	[5]	0	1,524
EV71 vaccine production facility and trial production of EV7 [Member]
Current deferred government grants	[5]	77	0
Non-current deferred government grants	[4]	2,828	3,223
Loan from Zhongguancun Development Group [Member]
Current deferred government grants	[6]	358	0
Non-current deferred government grants	[6]	0	376
Others [Member]
Current deferred government grants	[7]	78	81
Non-current deferred government grants	[7]	$ 678	$ 643
[1]	Deferred government grants included $1,126 (RMB 7.3 million) represents the unamortized portion of the amount that the Company received in 2007 for construction of a pandemic influenza vaccine plant and buildings of RMB 20 million (December 31, 2014 - $1,466 (RMB 9.1 million)). $278 (RMB 1.8 million) which will be amortized in 2016 was included in the current portion and $848 (RMB 5.5 million) which will be amortized after 2016 was included in the non-current portion of the deferred government grants. The production facility grant requires the Company to have the entire facility available to manufacture pandemic influenza vaccines at any given moment upon request by the Chinese government. The Company has fulfilled the conditions attached to the government grant. Government grant relating to these production facilities of $287, $290 and $237 for the year ended December 31, 2015, 2014 and 2013 were recorded as a reduction to depreciation expense.
[2]	Deferred government grants also included $467 (RMB 3.0 million) being the unamortized portion of the amount that the Company received in 2009 for purchasing equipment for H1N1 vaccine production with a total amount of $999 (RMB 6.2 million). The amount of $137 (RMB 0.8 million) which will be recognized in 2016 was included in the current portion and the amount of $330 (RMB 2.2 million) which will be recognized after 2016 was included in the non-current portion of deferred government grants. The Company has fulfilled the conditions attached to the government grant. Government grant relating to this production facility of $141, $143 and $119 for the year ended December 31, 2015, 2014 and 2013 were recorded as a reduction to the related depreciation expense.
[3]	Deferred government grants also included $62 (RMB 0.4 million) being the unamortized portion of the amount that the Company received in 2013 for purchasing equipment for H5N1 vaccine production. The amount of $15 (RMB 0.1 million) which will be amortized in 2016 was included in the current portion and the amount of $46 (RMB 0.3 million) which will be amortized after 2016 was included in the non-current portion of deferred government grants. Government grant relating to this production facility of $16 and $16 for the year ended December 31, 2015 and 2014 were recorded as a reduction to the related depreciation expense.
[4]	The Company received a government grant in the amount of $3,087 (RMB 20 million) for equipment purchase and construction of the Enterovirus 71 ("EV71") vaccine production facility. As of December 31, 2015, the Company has not fulfilled the conditions attached to the government grant. The Company obtained the Good Manufacturing Practices (“GMP”) certificate of its EV71 vaccine issued by the CFDA in January 2016, which was the final major condition attached to the grant. The amount of $259 (RMB 1.7 million) which will be amortized in 2016 was included in the current portion and the amount of $2,828 (RMB 18.3 million) which will be amortized after 2016 was included in the non-current portion of deferred government grants.
[5]	Deferred government grants also include $77 (RMB 0.5 million) that the Company received in 2015 for EV71 research and development. As the Company has obtained the Good Manufacturing Practices (“GMP”) certificate of its EV71 vaccine issued by the China Food and Drug Administration (“CFDA”) in January 2016, and is expected to fulfill the conditions within one year, the grant is recorded as a current government grant. As of December 31, 2015, the Company has obtained the new drug certificate and production license of EV71 vaccine issued by CFDA, and has fulfilled the conditions attached to three government grants for EV71 research and development with a total amount of $1,598 (RMB 10 million). These grants were recognized as income.
[6]	The Company received a loan of $1,934 (RMB 12 million) bearing an interest rate of 0.36% per year from Beijing Zhongguancun Development Group. The fair value differential (between the face value and the fair value using the effective interest rate method at the Company's borrowing rate of 6.9%) is recorded as current deferred government grant of $358 (December 31, 2014 - $376) (see note 11), since the loan will mature in 2016.
[7]	Deferred government grants also included $756 (RMB 4.9 million) in relation to four other research projects. As of December 31, 2015, the conditions attached to three of the four government grants totalling $678 (RMB 4.4 million) have not been fulfilled by the Company. As the Company does not expect to fulfill the conditions within one year, these grants are recorded as non-current deferred government grants (December 31, 2014 - $642 (RMB 4 million)). The Company expects to fulfil the conditions attached to one of the four grants and recorded $78 (RMB 0.5 million) as a current deferred government grant (December 31, 2014 - $81 (RMB 0.5 million)).

Deferred Government Grants (D91

Deferred Government Grants (Details Textual) $ in Thousands, ¥ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2013CNY (¥)	Dec. 31, 2007CNY (¥)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)
Proceeds from Government Grants Received	$ 236	¥ 1.5	$ 3,496	¥ 21.6	$ 842	¥ 5.2
Deferred Government Grants Current And Noncurrent	5,932		8,024
Deferred Government Grants Current	1,202		530
Deferred Government Grants Noncurrent	4,730		7,494
Beijing Zhongguancun Development Group [Member] | Term Loan For Funding Vaccine Research Project [Member]
Deferred Government Grants Current And Noncurrent	358		$ 376
Proceeds from Issuance of Long-term Debt, Total	$ 1,934	¥ 12
Debt Instrument, Interest Rate, Stated Percentage	0.36%							0.36%
Fair Value Inputs, Discount Rate	6.90%	6.90%	6.90%	6.90%
Grants For Pandemic Influenza Vaccine [Member]
Proceeds from Government Grants Received | ¥							¥ 20
Deferred Government Grants Current And Noncurrent	$ 1,126		$ 1,466					¥ 7.3	¥ 9.1
Deferred Government Grants Current	278							1.8
Deferred Government Grants Noncurrent	848							5.5
Government Grant Recorded as Reduction to Depreciation Expenses	287		290		237
Grants received in 2009 for H1N1 [Member]
Proceeds from Government Grants Received	999	¥ 6.2
Deferred Government Grants Current And Noncurrent	467							3
Deferred Government Grants Current	137							0.8
Deferred Government Grants Noncurrent	330							2.2
Government Grant Recorded as Reduction to Depreciation Expenses	141		143		119
Grants received in 2013 for H5N1 [Member]
Deferred Government Grants Current And Noncurrent	61							0.4
Deferred Government Grants Current	15							0.1
Deferred Government Grants Noncurrent	46							0.3
Government Grant Recorded as Reduction to Depreciation Expenses	16		16		16
Grants For E V71 Vaccine Research And Development [Member]
Deferred Government Grants Current And Noncurrent	77							0.5
Government Grant Recorded As Reduction Of Cost Of Goods Sold	1,598	10
Grants For Research And Development And Purchase Of Equipment For Ev71 Vaccine Production [Member]
Proceeds from Government Grants Received	3,087	20
Deferred Government Grants Current	259							1.7
Deferred Government Grants Noncurrent	2,828							18.3
Other research projects [Member]
Deferred Government Grants Current And Noncurrent	756							4.9
Deferred Government Grants Current	78		81					0.5	0.5
Deferred Government Grants Noncurrent	678		642					¥ 4.4	¥ 4
Interest subsidy, Rental Fees Subsidy and Other Government Grants [Member]
Additional Income from Government Grants	$ 308	¥ 1.9	$ 24	¥ 0.1	$ 0

Commitments and Contingencies92

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2015USD ($)
Minimum future rental payments under operating leases
2,016	$ 852
2,017	852
2,018	852
2,019	852
2,020	852
Thereafter	8,601
Total minimum future payments	$ 12,861

Commitments and Contingencies93

Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Lease Commitments
Operating Leases, Rent Expense, Net, Total	$ 852	$ 869	$ 847
Research and Development Arrangement [Member]
Operating Lease Commitments
Long-term Purchase Commitment, Amount	441
Capital Addition Purchase Commitments [Member]
Operating Lease Commitments
Long-term Purchase Commitment, Amount	$ 1,726

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	May. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares, Outstanding		56,906,561	55,809,661
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 2.13
Proceeds from Stock Options Exercised	$ 1	$ 732	$ 512	$ 848
Cash proceeds received on exercise of stock options for which shares were not issued till date		$ 18	$ 51	18
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	729,000
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001				$ 0.001
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash proceeds received on exercise of stock options for which shares were not issued till date			$ 51	$ 18
Range Of Exercise Prices Dollars 1.60 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares, Outstanding		115,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 1.60	$ 1.60	$ 1.60
Proceeds from Stock Options Exercised			$ 48,000	$ 360,600
Range Of Exercise Prices Dollars 2.37 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares, Outstanding		252,400
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 2.37	$ 2.37	$ 2.37
Proceeds from Stock Options Exercised			$ 191,300	$ 118,200

Stock Options (Details)

Stock Options (Details) - Stock options	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation assumptions for stock options
Expected volatility	51.42%	0.00%	0.00%
Risk-free interest rate	1.50%	0.00%	0.00%
Expected life (years)	5 years 6 months	0 years	0 years
Dividend yield	0.00%	0.00%	0.00%
Estimated forfeiture rate	7.00%	0.00%	0.00%

Stock Options (Details 1)

Stock Options (Details 1) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Stock options activity
Outstanding at the beginning of the period (in shares) | shares	637,200
Granted | shares	1,341,000
Exercised | shares	(367,900)
Forfeited / Expired | shares	(129,900)
Outstanding at the end of the period (in shares) | shares	1,480,400
Vested and expected to vest at the end of the period | shares	1,386,530
Exercisable at the end of the period | shares	139,400
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share) | $ / shares	$ 2.09
Granted (in dollars per share) | $ / shares	4.98
Exercised (in dollars per share) | $ / shares	2.13
Forfeited / Expired (in dollars per share) | $ / shares	1.71
Outstanding at the end of the period (in dollars per share) | $ / shares	4.73
Vested and expected to vest at the end of the period (in dollars per share) | $ / shares	4.72
Exercisable at the end of the period (in dollars per share) | $ / shares	$ 2.37
Aggregate Intrinsic Value
Outstanding at the beginning of the period | $	$ 1,997,644
Outstanding at the end of the period | $	1,459,330
Vested and expected to vest at the end of the period (in dollars) | $	1,389,866
Exercisable at the end of the period | $	$ 466,990

Stock Options (Details 2)

Stock Options (Details 2) - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at the beginning of the period (in shares) | shares	0
Granted | shares	729,000
Vested | shares	0
Forfeited / Expired | shares	0
Non-vested at the end of the period (in shares) | shares	729,000
Non-vested at the beginning of the period (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	4.98
Vested (in dollars per share) | $ / shares	0
Forfeited / Expired (in dollars per share) | $ / shares	0
Non-vested at the end of the period (in dollars per share) | $ / shares	$ 4.98

Stock Options (Details 3)

Stock Options (Details 3) shares in Thousands	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number of Options Outstanding (in shares)	1,480,400
Options Outstanding - Remaining Average Contractual Life (in years)	6 years 9 months 29 days
Options Exercisable - Number of Options Exercisable (in shares)	139,400
Options Exercisable - Remaining Contractual Life (in years)	1 year 11 months 26 days
Options Exercisable - Average Exercise Price (in dollars per share) | $ / shares	$ 2.37
Range Of Exercise Prices Dollars 2.37 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number of Options Outstanding (in shares)	139,400
Options Outstanding - Remaining Average Contractual Life (in years)	1 year 11 months 26 days
Options Outstanding - Average Exercise Price (in dollars per share) | $ / shares	$ 2.37
Options Exercisable - Number of Options Exercisable (in shares)	139,400
Options Exercisable - Remaining Contractual Life (in years)	1 year 11 months 26 days
Options Exercisable - Average Exercise Price (in dollars per share) | $ / shares	$ 2.37
Range Of Exercise Prices Dollars 4.98 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number of Options Outstanding (in shares)	1,341,000
Options Outstanding - Remaining Average Contractual Life (in years)	7 years 3 months 29 days
Options Outstanding - Average Exercise Price (in dollars per share) | $ / shares	$ 4.98
Options Exercisable - Number of Options Exercisable (in shares)	0
Options Exercisable - Remaining Contractual Life (in years)	0 years
Options Exercisable - Average Exercise Price (in dollars per share) | $ / shares	$ 0

Stock Options (Details Textual)

Stock Options (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May. 01, 2012	May. 31, 2015	Aug. 22, 2012	Dec. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,341,000
Allocated Share-based Compensation Expense					$ 952	$ 287	$ 281
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total		729,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 4.98
Common Stock, Par or Stated Value Per Share					0.001	$ 0.001
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total		729,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total		1,341,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 4.98
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date		Apr. 30, 2023
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				767,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price				$ 2.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 2.37	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					$ 104	$ 414	$ 420
Stock options [Member] | 2003 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					42,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.05
Share Based Compensation Arrangements By Share Based Payment Award Options Vesting Rights Percentage	10.00%					10.00%
Share Based Compensation Arrangements By Share Based Payment Award Options Quarterly Vesting Rights Percentage	10.00%
Share Based Compensation Arrangement By Share Based Payment Award Period From Initial Vesting Date For Vesting Of Remaining Options	27 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 1,118	$ 840	$ 1,344
Stock options [Member] | 2003 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum						10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Stock options [Member] | 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			4,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 2,557
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					52 months
Stock options [Member] | 2012 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share		$ 0.001						$ 0.001
Restricted Stock [Member] | 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 2,921
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					52 months

Statutory surplus reserves (Det

Statutory surplus reserves (Details Textual) ¥ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014CNY (¥)
Schedule Of Distribution Of Profits [Line Items]
Appropriation Of Net Income After Taxes To Statutory Surplus Reserve Fund Required Minimum Percentage	10.00%	10.00%
Reserve Level Threshold For Mandatory Transfer Percentage	50.00%	50.00%
Retained Earnings, Appropriated	$ 13,450,000		$ 12,627,000
Restricted Paid In Capital And Statutory Surplus Reserves	77,511,000		80,091,000		¥ 502	¥ 497
Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries	$ 66,590,000		$ 61,345,000
Sinovac Beijing
Schedule Of Distribution Of Profits [Line Items]
Percentage Of After Tax Profit Appropriated To General Reserve Funds	10.00%	10.00%	10.00%	0.00%
Appropriation Of After Tax Profit To General Reserve Fund	$ 823,000	¥ 5,200	$ 819,000	$ 0
Appropriation Of Net Income After Taxes To Staff Welfare And Bonus Fund	0		0	0
Dividends, Cash, Total	0		$ 0	$ 0
Tangshan Yian
Schedule Of Distribution Of Profits [Line Items]
Appropriation Of Net Income After Taxes To Staff Welfare And Bonus Fund	0
Appropriation Of Net Income After Taxes To Statutory Surplus Reserve Fund	0
Sinovac R&D
Schedule Of Distribution Of Profits [Line Items]
Appropriation Of Net Income After Taxes To Staff Welfare And Bonus Fund	0
Appropriation Of Net Income After Taxes To Statutory Surplus Reserve Fund	0
Sinovac Dalian
Schedule Of Distribution Of Profits [Line Items]
Appropriation Of Net Income After Taxes To Staff Welfare And Bonus Fund	0
Appropriation Of Net Income After Taxes To Statutory Surplus Reserve Fund	$ 0

Non-controlling Interests (Deta

Non-controlling Interests (Details Textual) $ in Thousands, ¥ in Millions	Apr. 08, 2013	Oct. 01, 2011USD ($)	Oct. 01, 2011CNY (¥)	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2011
Sinovac Beijing
Noncontrolling Interest [Line Items]
Increase in ownership (as a percent)		1.53%	1.53%
Increase in ownership by the entity in a subsidiary through contributing dividends declared to another subsidiary, but unpaid		$ 2,998	¥ 18.6
Adjustment To Additional Paid In Capital Due To Difference Between Fair Value Amount Acquired And Consideration Paid		$ 258	¥ 1.6
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		28.44%	28.44%			26.91%
Sinovac Beijing | Sino Bioway
Noncontrolling Interest [Line Items]
Percentage Of Equity Interest Transferred	26.91%
Sinovac Dalian
Noncontrolling Interest [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				45.00%	45.00%

Earnings (loss) per Share (Deta

Earnings (loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator
Income from continuing operations	$ 515	$ 1,188	$ 11,636
Less: Income (loss) attributable to non-controlling interests	861	515	2,928
Income (loss) attributable to shareholders of Sinovac from continuing operations	(346)	673	8,708
Income (loss) attributable to shareholders of Sinovac from discontinued operations	(728)	(1,524)	(1,266)
Net income (loss) attributable to shareholders of Sinovac	$ (1,074)	$ (851)	$ 7,442
Denominator
Basic weighted average number of common shares outstanding	56,313,927	55,681,076	55,301,276
Dilutive effect of stock options	0	433,126	501,062
Diluted weighted average number of common shares outstanding	56,313,927	56,114,202	55,802,338
Basic net income (loss) per share
Continuing operations	$ (0.01)	$ 0.01	$ 0.15
Discontinued operations	(0.01)	(0.03)	(0.02)
Basic net income (loss) per share	(0.02)	(0.02)	0.13
Diluted net income (loss) per share
Continuing operations	(0.01)	0.01	0.15
Discontinued operations	(0.01)	(0.03)	(0.02)
Diluted net income (loss) per share	$ (0.02)	$ (0.02)	$ 0.13

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets, Total	$ 202,984	$ 238,530
Mainland China
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets, Total	173,629	207,645
Hong Kong
Revenues from External Customers and Long-Lived Assets [Line Items]
Assets, Total	$ 29,355	$ 30,885

Segment Information (Details 1)

Segment Information (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	$ 67,414	$ 62,932	$ 71,774
Inactivated hepatitis vaccines
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	49,416	48,450	47,202
Influenza vaccines
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	12,674	12,131	12,156
H5N1
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	3,852	201	10,736
Mumps
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	$ 1,472	$ 2,150	$ 1,680

Segment Information (Details 2)

Segment Information (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	$ 67,414	$ 62,932	$ 71,774
Mainland China
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	66,779	61,955	70,647
Foreign countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales (note 23)	$ 635	$ 977	$ 1,127

Segment Information (Details Te

Segment Information (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Long-Lived Assets	$ 73,514	$ 76,846
Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Revenue, Net, Total	$ 9,128
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	14.00%

Collaboration Agreements (Detai

Collaboration Agreements (Details Textual) € in Thousands	Apr. 03, 2014	Dec. 14, 2011USD ($)	Mar. 12, 2009USD ($)	May. 31, 2014USD ($)	Aug. 18, 2009USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Mar. 31, 2015USD ($)
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred							$ 0		$ 0
Technology Transfer Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred											$ 300,000
Tianjing Can Sino Biotechnology Inc [Member] | Technology Transfer Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Payment for Transfer of Additional Serotypes and Related Technology		$ 300,000
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred						$ 1,200,000
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred for Agreement before Amendment						1,000,000
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred for Amended Agreement							200,000
Collaborative Arrangement Term of Agreement			8 years
Tianjing Can Sino Biotechnology Inc [Member] | Technology Transfer Agreement [Member] | Maximum [Member]
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments			$ 3,000,000
Royalty Payment on Net Sales			10.00%
Collaborative Arrangement Term of Agreement			8 years
Tianjing Can Sino Biotechnology Inc [Member] | Technology Transfer Agreement [Member] | Minimum [Member]
Royalty Payment on Net Sales			6.00%
National Institute of Health [Member] | Patent License Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement License Issue Royalty					$ 80,000
Collaborative Arrangements and Noncollaborative Arrangement License Royalty Payments Upon Achievement of Each Benchmark						330,000
Collaborative Arrangement Term of Agreement					8 years
Royalty Expense						9,000	8,000		$ 21,000
National Institute of Health [Member] | Patent License Agreement [Member] | Maximum [Member]
Royalty Payment on Net Sales					4.00%
National Institute of Health [Member] | Patent License Agreement [Member] | Minimum [Member]
Royalty Payment on Net Sales					1.50%
Collaborative Arrangements and Noncollaborative Arrangement Non Refundable Annual Royalty					$ 8,000
Medimmune LLC [Member] | H5N1 Licenses [Member]
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments				$ 0
Collaborative Arrangements and Noncollaborative Arrangement Milestone Payments Incurred						$ 9,900
Collaborative Arrangements and Noncollaborative Arrangement Licenses Fees and Royalties Paid										$ 3,400,000
Doses Of Vaccines Obtained From Government									3,000,000
Accrued Royalties, Current									$ 1,036,000
Institute For Translational Vaccinology [Member]
Collaborative Arrangements and Noncollaborative Arrangement Entrance Fees and Milestone Payments							2,406,000	€ 1,500
Entrance Fee Recorded As Research And Development Expense							665,000	500
Collaborative Arrangement Term of Agreement	50 years
Institute For Translational Vaccinology [Member] | Sabin Inactivated Polio Vaccine [Member]
Payment Made Recorded As Research And Development Expense							$ 125,000	€ 94

Subsequent Events (Details Text

Subsequent Events (Details Textual)	12 Months Ended
	Dec. 31, 2015$ / shares
Subsequent Event [Line Items]
Preferred Share Purchase Rights Conditions For Rights Exercise	(i) a person or group obtaining ownership of 15% or more of the Companys common shares or (ii) the commencement or announcement of an intention to make a tender offer or exchange offer, the consummation of which would result in the beneficial ownership by a person or group of 15% or more of the Companys common shares, in each case, without the approval of the Companys board of directors, each Right will entitle the holders, other than the acquiring person, to buy, at an exercise price of $30.00, one one-thousandth of a share of the newly created series A junior participating preferred shares of the Company, or the Series A Preferred Shares.
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 30
Board of Directors [Member]
Subsequent Event [Line Items]
Class of Stock Warrants or Right, Rights Redemption Price	$ 0.001

Condensed Financial Informat109

Condensed Financial Information of the Parent Company (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 63,834	$ 91,293	$ 106,517	$ 91,219
Prepaid expenses and other receivables	958	1,426
Total current assets	128,524	154,803
Total assets	202,984	238,530
Current liabilities
Accrued expenses and other payables	9,647	8,330
Total current liabilities	58,001	79,834
Total liabilities	64,243	96,804
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil	0	0
Common stock Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 56,906,561 (2014 - 55,809,661)	57	56
Additional paid-in capital	109,944	108,243
Accumulated other comprehensive income	8,110	12,022
Retained earnings	(8,281)	(6,384)
Total stockholders' equity	123,280	126,564
Total liabilities and equity	202,984	238,530
Parent Company
Current assets
Cash and cash equivalents	331	997
Prepaid expenses and other receivables	70	9
Amount due from subsidiaries	66,032	69,824
Dividend receivables	21,280	21,280
Total current assets	87,713	92,110
Investment in subsidiaries	41,711	38,616
Total assets	129,424	130,726
Current liabilities
Accrued expenses and other payables	666	584
Amount due to subsidiaries	5,478	3,578
Total current liabilities	6,144	4,162
Total liabilities	6,144	4,162
EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil	0	0
Common stock Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 56,906,561 (2014 - 55,809,661)	57	56
Additional paid-in capital	109,944	108,243
Accumulated other comprehensive income	8,110	12,022
Retained earnings	5,169	6,243
Total stockholders' equity	123,280	126,564
Total liabilities and equity	$ 129,424	$ 130,726

Condensed Financial Informat110

Condensed Financial Information of the Parent Company (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selling, general and administrative expenses	$ 37,436	$ 34,166	$ 33,611
Total operating expenses	45,266	45,399	41,323
Loss from operations	3,723	2,057	9,946
Interest income	1,155	2,684	2,167
Net income(loss)	(1,074)	(851)	7,442
Other comprehensive income (loss), net of tax of nil
Total comprehensive income (loss)	(4,986)	(2,970)	9,812
Parent Company
Selling, general and administrative expenses	2,563	2,466	2,710
Total operating expenses	2,563	2,466	2,710
Loss from operations	(2,563)	(2,466)	(2,710)
Other expense	(5,053)	0	0
Interest income	413	759	755
Equity earnings of subsidiaries, net of tax	6,129	856	9,397
Net income(loss)	(1,074)	(851)	7,442
Other comprehensive income (loss), net of tax of nil
Foreign currency translation adjustments	(3,912)	(2,119)	2,370
Total comprehensive income (loss)	$ (4,986)	$ (2,970)	$ 9,812

Condensed Financial Informat111

Condensed Financial Information of the Parent Company (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows provided by (used in) operating activities
Net income (loss)	$ (1,074)	$ (851)	$ 7,442
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
-stock-based compensation	952	287	281
Changes in:
- Prepaid expenses and other receivables	(434)	506	(243)
- Accrued expenses and other payables	(434)	(3,999)	4,450
Net cash provided by (used in) operating activities	3,383	(7,524)	6,448
Cash flows provided by financing activities
- Proceeds from issuance of common stock, net of share issuance costs	732	512	814
- Proceeds from shares subscribed	18	51	18
Net cash provided by financing activities	(24,196)	5,309	14,385
Cash flows provided by (used in) investing activities
Net cash provided (used in) investing activities	(4,417)	(10,913)	(5,133)
Decrease in cash and cash equivalents	(27,459)	(15,224)	15,298
Cash and cash equivalents, beginning of year	91,293	106,517	91,219
Cash and cash equivalents, end of year	63,834	91,293	106,517
Parent Company
Cash flows provided by (used in) operating activities
Net income (loss)	(1,074)	(851)	7,442
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
-stock-based compensation	952	287	281
-equity in (earnings) of subsidiaries	(6,129)	(856)	(9,397)
Changes in:
- Amount due from subsidiaries	3,792	(1,304)	2,505
- Prepaid expenses and other receivables	(61)	114	59
- Dividend receivables	0	0	1,043
- Amount due to subsidiaries	1,900	1,815	1,130
- Accrued expenses and other payables	82	(336)	(776)
Net cash provided by (used in) operating activities	(538)	(1,131)	2,287
Cash flows provided by financing activities
- Proceeds from issuance of common stock, net of share issuance costs	732	512	848
- Proceeds from shares subscribed	18	51	18
Net cash provided by financing activities	750	563	866
Cash flows provided by (used in) investing activities
-Investment in subsidiaries	(878)	165	(4,042)
Net cash provided (used in) investing activities	(878)	165	(4,042)
Decrease in cash and cash equivalents	(666)	(403)	(889)
Cash and cash equivalents, beginning of year	997	1,400	2,289
Cash and cash equivalents, end of year	$ 331	$ 997	$ 1,400